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LIST OF ABBREVIATIONS 
 
Actb: -Actin 
AD: Alzheimer’s disease 
ApoE: apolipoprotein E 
ApoER2: apolipoprotein E receptor 2 
APP: amyloid precursor protein 
BCA: bicinchoninic acid 
BSE: bovine spongiform encephalopathy 
CC: charged cluster 
CDK5: Cyclin-dependent kinase 5 
CID: collision induced dissociation 
CNS: central nervous system 
CJD: Creutzfeldt-Jakob disease 
CREB: cyclic AMP response element binding protein 
CRKL: Crk-like protein 
CTF: C-terminal fragment 
Cul5: Cullin 5 
Dab1: Disabled-1 
DIV: days in vitro 
dpi: days post inoculation 
Dpl: Doppel 
DSP: dithiobis(succinimidyl propionate) 
E: embryonic day 
EGF: epidermal growth factor 
ER: endoplasmic reticulum 
FBS: fetal bovine serum 
fCJD: familial Creutzfeldt-Jakob disease 
FFI: fatal familial insomnia 
GAPDH: glyceraldehyde 3-phosphate dehydrogenase 
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GPI: glycophosphatidylinositol 
GSK3β: glycogen synthase kinase 3β 
GSS: Gerstmann-Sträussler-Scheinker syndrome 
HC: hydrophobic core 
hFc: human Fc of immunoglobulin G1 
HRP: horseradish peroxidase 
iCJD: iatrogenic Creutzfeldt-Jakob disease 
KO: knockout 
LIS1: lissencephaly protein 1 
LTP: long term potentiation 
LRP8: low-density lipoprotein receptor-related protein 8 
moPrP-hFc: mouse prion protein fused to human Fc of immunoglobulin G1 
NCAM: neural cell adhesion molecule 
neo: neomycin 
NMDA: Nmethyl-d-aspartate 
NMDAR: Nmethyl-d-aspartate receptor 
OR: octapeptide repeats 
ORF: open reading frame 
P: postnatal day 
PBS: phosphate-buffered saline 
PBST: phosphate-buffered saline plus Tween-20 
PFHM: protein-free hybridoma medium 
PI3K: phosphatidylinositol 3-kinase 
PK: proteinase K 
PKA: protein kinase A 
PKC: protein kinase C 
PrPC: cellular prion protein 
PrPSc: scrapie prion protein 
PSD95: postsynaptic density protein 95 
recMoPrP: recombinant mouse prion protein 
RML: Rocky Mountain Laboratory 
RPTP: receptor protein tyrosine phosphatase  
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RR: Reelin repeats 
RT: room temperature 
sCJD: sporadic Creutzfeldt-Jakob disease 
SFK: Src family kinases 
STI1: stress-inducible protein 1 
TACE: TNF-converting enzyme 
TALEN: transcription activator-like effector nuclease 
TBS: Tris-Buffered Saline 
TBST: Tris-Buffered Saline plus Tween-20 
tcTPC: time-controlled transcardiac perfusion cross-linking 
tPA: tissue plasminogen activator 
TSE: transmissible spongiform encephalopathies 
Tubb3: βIII-tubulin 
UTR: untranslated region 
vCJD: variant Creutzfeldt-Jakob disease 
VLDLR: very-low-density lipoprotein receptor 
WB: Western blotting 
WT: wild-type 
YP: Tyrosine-phosphorylated 
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ABSTRACT 
 
Cellular prion protein (PrPC) has been widely investigated since its misfolded isoform, 
scrapie prion protein (PrPSc), which form aggregates that accumulate in the brain, 
causes prion diseases. The pathogenesis of prion diseases is currently under debate as 
they could be gain of toxic function consequences of the formation of PrPSc, or could 
be due to the loss of the normal physiological function of PrPC. For this reason, a better 
definition of the exact physiological function of PrPC represents a critical challenge 
since Prnp knockout mice lack striking phenotype. 
PrPC is highly abundant in the nervous system where it plays an important role in 
modulating cell signalling, acting as a dynamic scaffold for the assembly of many 
different signalling molecules at the neuronal surface. Importantly for the present 
study, it has been reported that PrPC is able to modulate Fyn, PI3K, AKT/PKB and 
GSK3β activity. All these intracellular kinases could be also regulated by yet another 
protein, Reelin, an extracellular matrix glycoprotein that activates a linear downstream 
signalling pathway. Interestingly, it has been reported that Reelin-signalling pathway is 
involved in both Alzheimer’s and prion diseases. Indeed, the intracellular adaptor 
protein Dab1 is able to affect APP processing and intracellular trafficking and to 
influence amyloid beta deposition in sporadic Creutzfeldt–Jakob disease. 
 
In the present study, taking advantage of different mouse models, we analysed the 
functional interaction between the prion protein and Dab1 signalling cascade from 
physiological and pathological point of view. 
In the first part of the project, using a Prnp knockout mouse model, we addressed the 
question whether PrPC could modulate the Reelin-signalling cascade. If this is the case, 
we could expect impairments in Reelin downstream signalling when PrPC expression is 
ablated. Indeed, the expression level and the activation state of Dab1 were evaluated 
in wild-type (Prnp+/+) and PrPC-null (Prnp0/0) mice brain and primary neuronal cultures. 
Reelin-conditioned medium, obtained from stably transfected HEK293T cells, was used 
to stimulate Dab1 activation in vitro and analyse a putative differential activation 
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between the two genotypes. Moreover, recombinant PrP and fusion PrP-hFc proteins 
were applied in the same system to evaluate the ability of PrPC to stimulate directly 
the signalling cascade. Dab1 protein resulted upregulated in Prnp0/0 brain in 
comparison to wild-type animals, with no changes in mdab1 gene transcription levels. 
Moreover, Prnp0/0 neurons appeared less responsive to Reelin stimulation than 
controls, leading to reduced phosphorylation of Dab1. Unfortunately, in our 
conditions, neither recombinant PrP nor PrP-hFc fusion protein were able to induce 
Dab1 phosphorylation, suggesting a modulating role, instead of a direct effect, of PrPC 
on the pathway. Expression analysis of different component of the pathway revealed 
no statistical differences between the two genotypes, with the exception of Fyn 
kinase, which resulted less phosphorylated in Prnp0/0 mice compared to wild-type 
controls. Immunoprecipitation experiments failed to unravel an interaction between 
PrPC and Reelin or its receptor ApoER2, suggesting that impairments in Dab1 
expression and phosphorylation are not due to a direct coupling between these 
proteins at the cell surface. Interestingly, in Prnp0/0 neurons, reduced levels of NCAM 
protein, a known PrPC interactor, were detected. 
In the second part of the project, taking advantage of different mouse models of 
Reelin pathway disruption, we addressed the opposite question to understand 
whether alteration of the Reelin-signalling pathway could affect the expression of PrPC. 
However, PrPC expression levels did not resulted significantly different in comparison 
to their respective controls in none of the genotypes analysed. These results suggest 
that, while PrPC is able to modulate Reelin-signalling cascade and in particular Dab1 
activation state, alterations of this pathway do not affect PrPC expression. 
Finally, terminally sick mice intracerebrally inoculated with RML prion strain were used 
as prion pathology model. Interestingly, in terminal stages of prion infection, Dab1 and 
Reelin receptors signals are no longer detectable. NCAM expression level seems not 
affected by prion infection, while Fyn kinase and AKT levels are reduced by 30% and 
50% respectively. Total Reelin amount is not modified by prion infection, while full-
length protein is reduced by almost 50% in RML-infected samples compared to 
controls with a concomitant 2-fold increase of both cleavage products. 
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Taken together, these findings suggest the existence of a functional interplay between 
prion protein and Dab1 signalling. Results obtained using PrPC-null mice as model of 
loss-of-function indicate a role for PrPC in promoting Dab1 signalling. However, as 
Reelin and its receptors are not affected by Prnp ablation, more likely PrPC indirectly 
modulate Dab1 signalling through NCAM and Fyn pathway. Interestingly, Dab1 
signalling resulted completely abolished in RML-inoculated terminally sick mice, used 
as prion disease model, together with strong alteration in Reelin processing, already 
reported in Alzheimer’s disease patients. Further experiments are in progress in order 
to clarify the mechanisms by which PrPC and PrPSc modulates Dab1 signalling pathway. 
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INTRODUCTION 
 
NEURODEGENERATIVE DISEASES 
 
Neurodegenerative disorders are characterized by progressive dysfunction and loss of 
neurons in specific areas of the nervous system, which determines the clinical 
manifestation of the disease. Pathogenic mechanisms shared by neurodegenerative 
disorders are protein misfolding and accumulation (Table 1), increased oxidative 
stress, impaired cellular metabolism, mitochondrial dysfunction and DNA damage, 
dysfunction of neurotrophins, neuroinflammation and induction of cell death [1].  
 
 
Table 1. Protein deposition in neurodegenerative diseases. Misfolding and accumulation of proteins in 
the nervous system represent a pathogenic mechanism shared by most neurodegenerative disorders 
[2]. 
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PRION DISEASES 
 
Prion diseases, also defined as transmissible spongiform encephalopathies (TSEs), are a 
group of fatal neurodegenerative disorders that may be characterized by infectious, 
genetic or sporadic aetiology [2]. These diseases may affect both animals and human, 
as shown in Table 2 [3]. 
 
 
Table 2. Prion diseases of humans and animals. Prion disorders may affect both animals and humans, 
and may be characterized by infectious, genetic or sporadic aetiology [3]. 
 
TSEs may present a heterogeneous spectrum of clinical symptoms, including dementia, 
insomnia, ataxia and many others. Indeed, different prion diseases may be 
characterized by different clinical features, that, besides clinical manifestation, include 
aetiology, incidence, affected brain regions and time course of the disease [2]. 
However, although the clinical presentation may differ among TSEs, these disorders 
are characterized by shared neuropathological hallmarks, as misfolded scrapie prion 
protein (PrPSc) aggregation, synaptic and neuronal loss, spongiform vacuolation and 
brain inflammation (Figure 1) [4]. 
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Figure 1. Neuropathological features of prion diseases. PrP
Sc
 deposits, synaptic damage and neuronal 
death, spongiform degeneration and brain inflammation are hallmarks of prion disorders [4]. 
 
The pathogenic agent at the basis of TSEs is named prion, a term introduced by Stanley 
B. Prusiner in 1982 to indicate a “proteinaceous infectious particle” with the unique 
capacity to self-replicate without requiring nucleic acids [5]. Indeed, the scrapie agent 
is resistant to inactivation by most procedures used to destroy nucleic acids [6]. 
Enzymatic digestion of brain extracts from prion-infected animals followed by size-
exclusion chromatographic analysis allowed the isolation of PrP27-30, a protein with a 
molecular weight of 27-30 kDa, which represents the resistant core of PrPSc [7]. 
Following sequencing of the PrP27-30 N-terminal domain, oligonucleotide probes were 
synthesized and used to screen cDNA libraries derived from healthy and scrapie-
infected hamster brains through Southern Blot, allowing the identification of the gene 
(Prnp) that encodes for an endogenous protein named cellular prion protein (PrPC) [8]. 
The fact that both PrPC and PrPSc are encoded by the same cellular gene suggested that 
the different properties of these two proteins are determined by post-translational 
modifications [9]. Indeed, according to the “protein-only” hypothesis, PrPSc results 
from the conformational change of the host-encoded PrPC, that is progressively 
converted into prions during the course of the disease [10]. 
PrPC and its pathological isoform PrPSc show different biochemical properties, due to 
post-translational modifications by which the -helical enriched structure of PrPC (40% 
-helix, 3% -sheet) is converted into a prominent -sheet folding (30% -helix, 45% 
-sheet). As a result of these structural changes, PrPSc is insoluble, prone to 
aggregation and partially resistant to proteases (Figure 2) [11, 12]. 
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Figure 2. The conversion of the natively folded PrP
C
 into PrP
Sc
 triggers disease. The structure of PrP
C
 
corresponds to the experimentally determined tridimensional conformation of the protein by nuclear 
magnetic resonance, while the structure of PrP
Sc
 corresponds to a model based on low resolution 
techniques [4]. 
 
Two mechanisms of prion conversion have been proposed (Figure 3). The “refolding” 
or template-assistance model hypothesizes an interaction between exogenously 
introduced PrPSc and endogenous PrPC, which is forced to convert itself into further 
PrPSc. A high-energy barrier prevents spontaneous conversion of PrPC into PrPSc. The 
“seeding” or nucleation-polymerization model proposes that PrPC and PrPSc are in a 
reversible thermodynamic equilibrium, and only if several monomeric PrPSc molecules 
are mounted into a highly ordered seed further monomeric PrPSc can be recruited and 
eventually aggregate to amyloid. Fragmentation of these aggregates results in the 
increase of seeding nuclei, which can recruit further PrPSc [13]. 
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Figure 3. Proposed mechanisms of prion conversion. Two models of the conversion of PrP
C
 into the 
misfolded PrP
Sc
 have been proposed. A) The refolding model proposes that there is an interaction 
between externally introduced PrP
Sc
 and cellular PrP
C
, which is forced to convert itself into further PrP
Sc
. 
B) The seeding model proposes that PrP
C
 and PrP
Sc
 are in a reversible equilibrium, and only if several 
monomeric PrP
Sc
 molecules are mounted into a highly ordered seed further monomeric PrP
Sc
 can be 
recruited and eventually aggregate to amyloid [13]. 
 
Although the formation and the progressive accumulation of PrPSc in the brain is 
thought to represent the pathogenic event leading to neurodegeneration, the 
underlying mechanisms are still under debate [4]. Many evidences point to a gain-of-
function mechanism, meaning that the misfolded protein is able to induce direct 
neurotoxicity. Indeed, purified PrPSc from the brain of infected animals triggers 
apoptosis of treated N2a neuroblastoma cells [14], while prion protein oligomers 
resulted to be neurotoxic both in vitro and in vivo [15]. However, resistance of Prnp 
knockout mice to prion infection [16] underlines that PrPSc is not sufficient to develop 
the disease. Moreover, high levels of accumulated PrPSc within PrPC-expressing tissue 
grafted into the brains of PrPC-null mice do not propagate the infectivity in the host 
tissue [17]. Finally, progressive propagation of PrPSc in glial cells is not able to induce 
death of surrounding neurons depleted of PrPC [18], also arguing against a direct 
neurotoxic effect of misfolded PrPSc. Indeed, the loss of a critical physiological function 
of PrPC may represent a possible mechanism by which PrPSc formation leads to 
neurodegeneration. On the other hand, the lack of striking phenotypes and the 
absence of neurodegeneration in the brain of Prnp knockout mice argue against the 
 14 
loss-of-function hypothesis [19, 20]. Consequently, it is still under debate whether 
prion toxicity is mediated by gain-of-function of misfolded protein or loss-of-function 
of normal prion protein, or, more likely, by a combination of the two. Indeed, multiple 
mechanisms may contribute to the pathology of prion diseases, leading to progressive 
neurodegeneration.  
 
HUMAN PRION DISEASES 
 
Prion diseases may occur as sporadic, genetic and infectious disease in humans [2]. 
The first cases of human prion disease, Creutzfeldt-Jakob disease (CJD), were reported 
in 1920s. The number of human TSEs has increased and now includes Gerstmann-
Sträussler-Scheinker syndrome (GSS), fatal familial insomnia (FFI) and Kuru (Table 2) 
[21]. 
Creutzfeldt-Jakob disease was originally described as a sporadic disease with no known 
cause (sporadic CJD, sCJD). CJD affects about 1 person over one million per year, and it 
is characterized by rapid cognitive decline, causing dementia, and cerebellar symptoms 
as ataxia [21]. It has been hypothesized that sCJD could be caused by somatic 
mutations in the PRNP gene, or by unrecognized infections or by the propensity of PrPC 
to self-assemble into PrPSc aggregates, thus initiating prion replication. However, none 
of these hypotheses have been proven, thus the cause of sCJD remains unknown [21, 
22]. It has been proposed that the clinicopathological phenotypes of sCJD patients can 
be determined by the type of PrPSc (named types 1 and 2) that accumulates in the 
affected brains and by the genotype at codon 129 of the PRNP gene, the site of a 
methionine/valine polymorphism [23]. Type 1 and type 2 PrPSc differ by the size of 
their proteinase K (PK) resistant core (21 and 19 kDa, respectively), that depends on 
the PK cleavage site (residues 82 and 97, respectively) [24]. 
Variant CJD (vCJD) resulted from transmission of prions from cattle infected with 
bovine spongiform encephalopathy (BSE) to humans through the consumption of 
contaminated beef products [22]. Another infectious form of CJD is the iatrogenic CJD 
(iCJD), which is accidentally transmitted by medical or surgical procedures, such for 
example corneal transplantation, dura mater grafts, treatment with human growth 
hormone and gonadotrophin [21]. Moreover, some cases of iCJD were caused by the 
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use of inefficiently sterilized implanted electrodes and instruments during 
neurosurgical procedures [22]. Besides, infectious forms of prion diseases include 
Kuru, an endemic disease among some tribes of New Guinea, which is transmitted by 
ritual cannibalism of dead relatives [21, 22]. 
Several mutations in the PRNP gene have been identified in families with genetic forms 
of prion diseases, such as familial CJD (fCJD), Gerstmann-Sträussler-Scheinker 
syndrome (GSS) and fatal familial insomnia (FFI). fCJD may be caused by point 
mutations affecting the region between the second and third helix of the C-terminus 
or by insertions in the octarepeat region at the N-terminus. fCJD is an autosomal 
dominant inherited disease, characterized by different clinicopathological phenotypes 
depending on mutation type, codon 129 polymorphism and many other factors [21]. 
Interestingly, the point mutation D178N can cause either fCJD or FFI, depending on the 
polymorphism present at codon 129. D178N coupled with 129MV (heterozygosity 
methionine-valine) causes fCJD, with dementia and widespread deposition of PrPSc, 
while in presence of 129MM (homozygosity for methionine) it associates with FFI, with 
thalamic deposition of prions [22]. Indeed, FFI is a genetic prion disease characterized 
by disruption of normal sleep-wake cycle, sympathetic over activity, endocrine 
abnormalities and impaired attention [21]. Besides, GSS, another autosomal dominant 
form of prion disease, is characterized by earlier age at onset, longer disease duration 
and more prominent cerebellar ataxia than fCJD [21]. The most common mutation 
causing GSS is the point mutation P102L of the PRNP gene [25]. 
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THE CELLULAR PRION PROTEIN 
 
The cellular prion protein is encoded by Prnp gene (on mouse chromosome 2, PRNP on 
human chromosome 20), and is highly conserved across species. The Prnp gene is a 
single-copy gene that contains either three (mouse, rat, bovine, sheep) or two exons 
(humans, hamster). However, the entire open reading frame (ORF) of PrPC is contained 
into a single exon in all the known Prnp genes (Figure 4) [26-29]. 
 
 
Figure 4. The murine PrP gene (Prnp). The murine PrP gene possesses three exons; exon 3 contains the 
entire open reading frame (ORF) and a 3' untranslated region (3' UTR) [30]. 
 
PrPC is a ubiquitously expressed endogenous glycoprotein, which is mainly exposed to 
the outer layer of the cell surface as an N-glycosylated glycophosphatidylinositol (GPI)-
anchored protein (Figure 5) [31, 32]. 
 
 
Figure 5. Mature form of the cellular prion protein, PrP
C
. PrP
C
 is a GPI-anchored protein, with a flexible, 
random coil N-terminal domain and a globular C-terminal domain. The N-terminal domain of PrP
C
 
contains octapeptide repeats (in light blue), which can bind divalent cations such as copper ions. The C-
terminal domain of PrP
C
 contains three -helices (in pink) and an antiparallel β-pleated sheet formed by 
two β-strands (in yellow). Depending on the glycosylation status of two Asn residues, PrP
C
 can be found 
as un-, mono- or di-glycosylated protein [33]. 
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PrPC precursor protein presents two signal peptides. At the N-terminal region, a signal 
peptide of 22 amino acids targets the protein to the secretory pathway, where it 
undergoes a glycosylation process, while at the C-terminal region a second signal 
sequence of 23 amino acids is needed for the attachment of the GPI moiety at the C-
terminus of PrPC (Figure 6). After proteolytic cleavage and post-translational 
modification in the endoplasmic reticulum (ER) and in the Golgi, PrPC is exported to the 
cell surface as a mature protein of 208-209 amino acids. 
The mature form of PrPC structurally consists of two domains, as determined by 
nuclear magnetic resonance [34]: an N-terminal flexible unfolded domain and a C-
terminal folded globular domain. The N-terminal domain consists of a random coil 
sequence of about 100 amino acids, that contains the octapeptide repeats (OR), that 
confer to the protein the ability to bind copper ions [35], and two positively charged 
clusters, CC1 and CC2. The globular domain presents three -helices and two -strands 
organized in an antiparallel -pleated sheet. A single disulphide bond links cysteine 
residues 178 and 213 (mouse numbering). Two glycosylation sites are presents in the 
C-terminus of PrPC (Asn180 and Asn196). The glycosylation status of these two 
residues determines whether PrPC is expressed as un-, mono- or di-glycosylated 
protein [36]. N- and C-terminal domains are linked by the hydrophobic core (HC), a 
sequence of hydrophobic amino acids (Figure 6) [34]. 
 
 
Figure 6. Outline of the primary structure of the cellular prion protein including post-translational 
modifications. A secretory signal peptide is located at the extreme NH2 terminus. CC1 and CC2 indicate 
the charged clusters. OR indicates the four octapeptide repeats. HC defines the hydrophobic core. MA 
denotes the membrane anchor region. S-S indicates the single disulphide bridge, and the glycosylation 
sites are designated as CHO. The numbers describe the position of the respective amino acids [37]. 
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PrPC EXPRESSION AND SUBCELLULAR ENVIRONMENT 
 
PrPC is highly expressed in the developing and mature nervous system, although 
differences in its content are observed among brain regions, cell types and neurons 
with distinct neurochemical phenotypes [38]. However, many non-neuronal tissues 
also express PrPC, such as blood lymphocytes, gastro-epithelial cells, heart, kidney and 
muscles [39, 40]. Despite the special relevance of PrPC in the nervous system, its 
expression pattern suggests a role for PrPC not limited to this tissue. 
PrPC expression in the nervous system starts from the embryogenesis and is 
developmentally regulated, generally increasing during brain development [41-45].  
Indeed, PrPC expression increases markedly during brain development, starting from 
the embryogenesis and reaching a peak at the end of the synaptogenesis [44]. 
Regional differences in PrPC expression were observed, with the highest PrPC 
expression in structures characterized by plasticity during adulthood, such as the 
hippocampus and the olfactory bulb, and lower expression in thalamus and cortex 
(Figure 7) [44]. 
 
 
Figure 7. PrP
C
 protein expression in the developing and adult hamster brain. A) PrP
C
 expression 
increases markedly during brain development, from postnatal day 0 (P0) to P14, slightly decreasing 
during adulthood. B) Regional differences in PrP
C
 expression were observed, with the highest PrP
C
 
expression in the hippocampus and the olfactory bulb, and lower expression in thalamus and cortex 
[44]. 
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Spatiotemporal analysis of PrPC expression during mouse central nervous system (CNS) 
development revealed that the hippocampus, the thalamus and the hypothalamus are 
the regions with the earliest and the highest PrPC expression. During brain early 
postnatal development, PrPC is highly expressed in the hippocampus, and in particular 
the stratum lacunosum-molecolare, a synapse-rich region, revealed the highest PrPC 
expression. Moreover, high PrPC expression was also observed in some specific white 
matter structures, such as the hippocampal fimbria, the stria terminalis and the 
fasciculus retroflexus (Figure 8) [45].  
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Figure 8. PrP
C
 expression in the hippocampus during development. A, B) At P7 PrP
C
 (in red; A) is 
detected throughout the hippocampus, and in particular at high levels in the stratum lacunosum-
molecolare (str l m), a synapse-dense region. No signal for PrP
C
 is detected in the cortex. A merged 
image is shown in B (PrP
C
, in red; neurofilament, in green; nuclei signals in blue). C–H) PrP
C
 is specifically 
and highly expressed by the fimbria of the hippocampus and the stria terminalis at P7 (C, D). The fimbria 
of the hippocampus (Fi) and the stria terminalis (St) express high level of PrP
C
 also at embryonic stages 
(E18.5), and progressively increase the level of expression during postnatal development: P1 (F), P4 (G), 
and P7 (H). I, J) Higher magnification of longitudinal (I) and coronal (J) section of the fimbria of the 
hippocampus and the stria terminalis, highlighting the net boundaries of PrP
C
 expression between other 
brain regions and these structures. Scale bars ¼ 50 lm [45]. 
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Concerning subcellular localization, PrPC is mainly located at the synapses, both 
presynaptically and postsynaptically [40, 46-49]. During its normal life cycle, PrPC is 
bound to the cell membrane via a GPI-anchor and it is mainly found in specialized 
membrane regions, named lipid rafts, that are detergent-insoluble membrane 
microdomains enriched in cholesterol and sphingolipids [38]. PrPC is recycled between 
the cell surface and the endocytic compartment via two mechanisms. In neurons, PrPC 
is internalized through clathrin-coated vescicles, while in other cell types, such as in 
glial cells, PrPC is endocyted through a caveolin-mediated mechanism [38, 50, 51]. 
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PHYSIOLOGICAL FUNCTION OF CELLULAR PRION PROTEIN 
 
During the last few decades, many efforts have been carried out to investigate the 
physiological function of PrPC. All these attempts were focused using multiple 
approaches, such as the identification of interaction partners, genetic studies of 
human PRNP locus, overexpression of ectopic PrPC in several cell types and organisms, 
and PrPC expression ablation in mice, cows and goats (Figure 8). Despite these studies 
have provided many hints on PrPC function, a conclusive view is still missing [52]. 
 
 
Figure 9. Different approaches to study the physiological function of PrP
C
. Many approaches to study 
the normal function of PrP
C
 have been used, none of which have conclusively shown PrP
C
 function. 
Interacting partners of PrP
C
 have yielded many interesting candidates, while human genetic studies have 
found associations of PrP
C
 with diseases beyond prion disease and even to learning and memory. Over- 
and ectopic-expression studies constitute another approach to determine the function of PrP
C
, together 
with prion protein knockouts, that provided some interesting clues to the physiology of PrP
C
 [52]. 
 
INSIGHTS FROM KNOCKOUT MODELS 
 
The high conservation of PrPC among mammalian species suggests that this protein 
may play some critical physiological roles during evolution [22]. Indeed, great 
expectations were placed on the generation of PrPC-deficient mouse models and 
several groups independently generated several knockout mice, taking advantage of 
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homologous recombination, to investigate the physiological functions of PrPC (Figure 
10a). 
The first Prnp knockout mouse strains, Zurich I and Edinburgh, were generated by 
inserting neomycin resistance (neo) cassette into exon 3 of the Prnp gene. These mice, 
in which the genetic modification is restricted to Prnp ORF, develop and reproduce 
normally, do not show gross behavioural and learning impairments and failed to show 
any striking phenotype [19, 53]. However, genetic compensation and developmental 
plasticity may mask the effects of PrPC ablation [52]. Indeed, more recent studies 
pointed out that these mice present subtle phenotypes, such as demyelinating 
pathology in peripheral nervous system in aging [54], alteration of circadian rhythms 
[55], impaired long term potentiation (LTP) [56], enhanced susceptibility to oxidative 
stress [57, 58] and excitotoxicity [59]. 
In contrast, another set of knockout models, Nagasaki, Rcm0 and Zurich II, develop 
normally but undergo severe ataxia during aging, due to cerebellar atrophy and loss of 
Purkinje cells [60]. These mice were generated by a knockout procedure that disrupted 
not only the Prnp ORF, but affected also its flanking regions, leading to the formation 
of a chimeric transcript between Prnp and a paralog gene, Prnd, located 16 kb 
downstream (Figure 10b,c) [61]. Prnd encodes for an N-glycosylated GPI-anchored 
protein named Doppel (Dpl), normally expressed in many tissues but not in the adult 
brain, which physiological function is still unknown [62]. As a consequence of the 
deletion strategy used to generate these models, Prnd is placed under the control of 
Prnp promoter, leading to ectopic expression of Dpl protein. Levels of Dpl expression in 
the brain were inversely correlated to the onset of the phenotype [63]. Reintroduction 
of Prnp in these mice rescued the phenotype, thus PrPC counteracts Dpl neurotoxicity 
through a still unknown mechanism [64]. Indeed, ectopic expression of Dpl in the 
absence of PrPC, rather than absence of PrPC itself, causes the strong phenotype 
observed in these knockout models. 
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Figure 10. Prnp knockout strategies and their consequences. A) Various strategies used to target Prnp 
by homologous recombination. The black boxes represent PrP ORFs; white boxes, non-coding Prnp 
regions; grey boxes, inserted sequences; dotted line, deleted regions; neo, neomycin 
phosphotransferase; HPRT, hypoxanthine phosphoribosyltransferase; loxP (black arrowhead), a 34-bp 
recombination site from phage P1. B) Coding and non-coding exons of Prnp, Prnd and intergenic exons 
of unknown function. C) Exon skipping leads to expression of Doppel under the control of the Prnp 
promoter. Deletion of the splice receptor site upstream of the third Prnp exon entails the formation of 
several chimeric mRNAs comprising the first two exons of Prnp [65]. 
 
All Prnp knockout mice presented above were generated by means of homologous 
recombination in embryonic stem cells obtained from the 129 strain of mouse, and 
then backcrossed to non-129 strains. This results in the presence of systematic genetic 
confounders at the Prnp locus. More recently, in order to overcome these limitations, 
a new co-isogenic line of Prnp knockout mice (Zurich-3, ZH3) was generated using 
transcription activator-like effector nuclease (TALEN)-based genome editing on a pure 
C57BL/6J genetic background [66]. 
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Unfortunately, due to the lack of striking phenotypes, data from knockout models 
failed to conclusively define any important role for PrPC in the physiology of the 
nervous system. However, upon deeper examination many subtle phenotypes 
emerged, thus several PrPC physiological functions have been proposed. PrPC 
modulates sleep-wake cycles, hippocampal-dependent spatial learning and memory 
formation [21, 33, 38]. At the cellular level, PrPC plays an anti-apoptotic role and 
protects against oxidative stress [21]. Indeed, a recent work from our group reported 
that PrPC exerts its neuroprotective role modulating NMDA receptor activity [67]. 
Moreover, many studies reported a role for PrPC in modulating synaptic activity, 
neuronal excitability and neurite outgrowth. In the peripheral nervous system, PrPC is 
involved in myelin maintenance. Besides these functions strictly related to the nervous 
system, PrPC also seems to play immunomodulatory functions and to affect 
hematopoietic and neural stem cell biology [21, 33, 52]. 
Figure 11 summarizes some of the cellular processes in which PrPC is involved in the 
nervous system. 
 
 
Figure 11. Physiological processes involving PrP
C
. Neurite outgrowth, including growth of axons and 
dendrites, was observed to be reduced in neurons lacking PrP
C
. PrP
C
 has been reported to promote 
neuronal survival, in particular following apoptotic or oxidative stress. Cerebellar granule cell apoptosis 
was observed in mice expressing toxic N-terminal deletion mutants of PrP. In addition, the latter 
transgenic mice show an impaired maintenance of myelinated axons in the white matter. Another site 
of PrP
C
 action might be the synapse, which is often affected in the first stage of prion diseases and 
whose formation was found to be reduced in neuronal cultures devoid of PrP
C
. Furthermore, 
electrophysiological studies indicate a role of PrP
C
 in synapse function, especially in neurotransmitter 
release [21]. 
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PrPC SIGNALLING 
 
Several lines of evidence suggest that PrPC can act as a cell-signalling molecule, playing 
a role in signal transduction in response to interactions with multiple binding partners. 
Thus, PrPC can link stimuli between the extracellular environment and the cell, being 
able to participate in multiple neuronal processes, ranging from survival to synaptic 
plasticity [68, 69]. In line with the topic and the aim of this thesis, the particular role of 
PrPC in cell signalling will be described in detail in the following paragraphs. 
 
SEARCH FOR PRION PROTEIN INTERACTORS 
 
The subcellular localization of PrPC in lipid rafts may indicate a possible involvement in 
signal transduction. Indeed, many signalling molecules are located in these particular 
regions of the plasma membrane, which are considered “hot spots” for signal 
transduction [70]. As the identification of cellular partners of PrPC may help to unravel 
its physiological functions, many studies were aimed to disclose PrPC interactome at 
the cell membrane. Indeed, signal transduction requires the interaction between a 
ligand and its receptor, that is usually a transmembrane protein with a cytosolic 
domain that transfers the signal from the extracellular environment to the intracellular 
compartment [71]. PrPC is a GPI-anchored protein bound to the outer leaflet of the cell 
membrane, thus it lacks the cytosolic domain required for the signal transduction. 
Indeed, a lot of efforts were done to identify possible interactors of PrPC that could act 
as co-receptors. 
Among them, neural cell adhesion molecule (NCAM) was identified as binding partner 
of PrPC applying a mild in situ crosslinking method that maintains the 
microenvironment of PrPC on the membrane of mouse neuroblastoma cells (N2a) [72]. 
More recently, NMR structural studies revealed that the regions involved in this 
functional interaction are the N-terminal region of the human PrPC and the second 
module of NCAM Fibronectin type-3 domain [73]. The physiological relevance of this 
interaction in modulating neurite outgrowth was proven [74, 75] and will be discussed 
below. 
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Other well characterized interactors of PrPC are laminin receptor precursor and laminin 
receptor [76, 77], the extracellular matrix glycoprotein laminin [78] and the co-
chaperone stress-inducible protein 1 (STI1) [79]. 
More than 20 proteins residing in the proximity of PrPC were identified using a time-
controlled transcardiac perfusion cross-linking (tcTPC) strategy. This novel technique 
was used for the study of protein interactions in complex tissues, and in particular to 
study the cellular microenvironment of PrPC in the brain. Many of the identified 
proteins are involved in cell adhesion and neurite outgrowth (Table 3) [80]. 
Interestingly, using this technique, amyloid precursor protein (APP) appeared to form a 
complex with PrPC. More recently, PrPC was identified as a functional receptor for A-
oligomers [81], the molecular species that triggers toxicity in Alzheimer’s disease (AD). 
However, the exact role of PrPC in the pathogenesis of AD is still under debate [82-84]. 
 
 
Table 3. The molecular microenvironment of PrP in the living brain consists predominantly of 
membrane proteins that harbor immunoglobulin C2 and/or FNIII-like domains. tcTPC of outbred mice 
followed by high stringency immunoaffinity purification and mass spectrometry enabled identification 
of more than 20 protein components of PrP containing crosslinking complexes. All proteins listed were 
identified with high confidence based on strong and unique collision induced dissociation (CID) spectra 
from at least two peptides. Proteins are listed in order, with the position of a given protein in the table 
reflecting the percentage of primary structure corresponding to the combined unique CID spectra. Note 
the predominance of GPI-anchored proteins and that all entries are either integral membrane proteins 
or are known to reside in spatial proximity to the cell membrane [80]. 
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Recently, a more physiological approach was used to characterize the interactome of a 
fully functional Myc-tagged PrPC, taking advantage of co-immunoprecipitation strategy 
under native conditions. Several proteins interacting with PrPC were identified by mass 
spectrometry and many of them resulted to be involved in myelin maintenance [85]. 
The interactions between PrPC and its binding partners have been functionally 
validated and resulted involved in many cellular processes, such as neuroprotection, 
cell death and neurite outgrowth. 
 
PrPC AND THE SRC FAMILY KINASES (SFK) 
 
Src family kinases are non-receptor tyrosine kinases that are generally associated with 
the inner face of the cell membrane, that integrate several signals transduced by the 
cell surface receptors in response to a large number of extracellular stimuli. Src kinases 
play a role in many cellular events, such as cell growth and proliferation, cell adhesion 
and migration, differentiation, survival and death. This family of kinases is composed 
by nine members: Src, Yes, Fyn, Fgr, Lyn, Hck, Lck and Blk [86, 87]. 
The first demonstration of PrPC involvement in cell signalling was achieved using 
antibodies against the prion protein in order to mimic a putative physiological ligand. 
Indeed, antibody cross-linking of PrPC at the cell membrane of 1C11 cells, a murine line 
that can differentiate in serotonergic and noradrenergic neurons, led to 
phosphorylation of p59fyn kinase [88]. Moreover, the Fyn kinase inhibitor PP2 
completely abolished the downstream activation of ERK kinase in the same system 
[89]. As Fyn was shown to mediate NCAM-induced neurite outgrowth [90], and as PrPC 
is known to directly interact with NCAM at the neuronal surface [72], more recently 
the role of PrPC in NCAM-mediated signalling was unravelled. Indeed, the interaction 
with PrPC promotes NCAM recruitment to lipid rafts and regulates Fyn kinase activity 
through the receptor protein tyrosine phosphatase  (RPTP) and stimulate neurite 
outgrowth [74]. Moreover, PrPC is not only able to regulate neurite outgrowth by 
interaction with NCAM in cis, but also in trans interactions between NCAM and 
recombinant PrP added to the culture medium are able to provide the same result, 
thus supporting previously reported data [91]. More recently, we confirmed the role of 
recombinant full-length PrP (recPrP) in promoting neurite outgrowth. Notably, PrPC 
 29 
knockout neurons were insensitive to recPrP stimulation, thus suggesting that recPrP 
functions as a signaling molecule and its homophilic interaction with membrane-
anchored PrPC may promote neurite outgrowth. Interestingly, pre-treatment of the 
neurons with a selective Src family kinases inhibitor or with a monoclonal antibody 
against NCAM strongly impairs the response to recPrP, thus supporting the role of 
NCAM and SFKs in the PrPC signalling complex [75]. Finally, in PrP-null brains, increased 
total levels, but lower activation, of Fyn have been reported [74]. 
The functional interaction between prion protein, NCAM and Fyn kinase was also 
examined in prion diseases, in order to evaluate the possible involvement of the 
NCAM-mediated Fyn signalling in prion propagation. In vivo experiments on knockout 
animals failed to show differences in incubation time and PrPSc deposition in NCAM-/- 
and in Fyn-/- mice compared to wild-type (WT) animals [72, 92]. However, increased 
levels of phosphorylated Fyn were detected both in chronically prion-infected cell lines 
and in animal models of prion disease [93, 94]. 
Interestingly, it was recently shown that the detrimental effects on synaptic function 
mediated by interaction between PrPC and A-oligomers also depend on Fyn 
activation, which triggers the phosphorylation of the NR2B subunit of NMDA receptors 
and their loss from the post-synaptic membrane [65]. 
 
More recently, it was reported that PrPC has the ability to recruit another member of 
the Src family kinases, the Lyn kinase [95], which was previously found to be present in 
the microenvironment of PrPC at the plasma membrane of primary cerebellar neurons 
[96]. In this work, GSK3β, a kinase whose inhibition is neuroprotective, was also 
reported to be a downstream target of PrPC. Indeed, the PrPC-dependent GSK3β 
inactivation resulted to be mediated by a caveolin-Lyn complex located on neuronal 
cell bodies. Moreover, in vivo data highlighted increased GSK3β activity in PrP-null 
mouse brain [95]. 
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PrPC AND THE PI3K/AKT PATHWAY 
 
The phosphatidylinositol 3-kinase/AKT (PI3K/AKT) pathway plays a role in the 
regulation of cellular processes, such as neuronal survival and apoptosis [97], and in 
cancer progression [98].  
The first demonstration of a functional interaction between PrPC and the PI3K/AKT 
pathway was provided by the use of the PI3K inhibitor wortmannin, that was able to 
block axon elongation induced by PrP-Fc fusion protein in mouse cerebellar granules 
[99]. Later on, significantly higher PI3K activity levels were found in both mouse 
neuroblastoma N2a cells and immortalized hippocampal HpL cells transfected with 
wild-type PrPC in comparison to their controls. Moreover, PI3K activity was found to be 
reduced in PrP-null mouse brain compared to WT animals [100]. PI3K is known to be 
sensitive to superoxide and hydrogen peroxide [101], and to be activated by copper(II) 
ions [102]. Indeed, it was shown that the recruitment of PI3K by PrPC promotes cell 
survival in response to oxidative stress and serum deprivation, and that this PrPC-
mediated effect is dependent on copper binding to the octapeptide region of the prion 
protein [100].  
These findings suggest that PrPC may exert a neuroprotective function, and its absence 
may increase susceptibility to neuronal injuries. Indeed, it was shown that both 
transient and permanent ischemia result in increased infarct volumes in Prnp knockout 
mice compared to WT controls. Moreover, in PrPC-null mice reduced phosphorylation 
of AKT and increased activation of caspase-3 were observed [103]. Interestingly, PrPC 
overexpression is able to reduce the infarct volume after ischemic injury, but does not 
affect AKT phosphorylation [104]. 
Recently, it has been shown that protein synthesis in neurons is enhanced by PrPC-STI1 
interaction by the PI3K-mTOR signalling pathway, and that this effect is responsible for 
neuroprotection and neuritogenesis. Interestingly, protein synthesis stimulation 
mediated by PrPC-STI1 is impaired in neuronal cell lines chronically infected with 
prions, as well as in primary cultured hippocampal neurons acutely exposed to PrPSc. 
Indeed, these findings indicate that the impairment of this process during prion 
infection may contribute to neurodegeneration [105]. 
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OTHER PrPC SIGNALLING EFFECTORS 
 
Other reported intracellular effectors of PrPC signalling include the protein kinase A 
(PKA) [106-108] and protein kinase C (PKC) [91, 109], the MAP kinases ERK1/2 [89, 106, 
107, 110], the enzyme NADPH oxidase [89] and the metalloprotease TNF-converting 
enzyme (TACE) [111]. Moreover, functional interaction with several transcription 
factors, such as CREB, Egr-1 and c-fos [112], as well as with calcium signalling [113-116] 
have been reported. 
A summary of PrPC signalling effectors is reported in Table 4. 
 
 
Table 4. Downstream targets of PrP
C
-mediated signalling in a neuronal context. The diverse array of 
PrP
C
 signalling effectors is reported, together with the observed physiological response [69]. 
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The data obtained in the presented literature suggest that PrPC may act as a dynamic 
scaffolding protein on the cell surface with the ability to assemble with multiple sets of 
interactors to trigger different signalling cascades, according to the cell type and 
physiological state [38, 68]. 
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REELIN/DAB1 SIGNALLING CASCADE 
 
As previously discussed, of relevance for the present study, it has been reported that 
PrPC directly interacts with NCAM at neuronal surface, thus regulating Fyn kinase 
activity [74], and could affect PI3K [100], Akt/PKB [103] and GSK3β [95] activity. All 
these intracellular kinases could be also regulated by yet another protein, Reelin, an 
extracellular matrix glycoprotein that activates a linear downstream signalling pathway 
[117]. Besides signal transduction, Reelin is also able to exert its biological functions via 
proteolytic activity as a serine protease of the extracellular matrix, having an 
important role in the modulation of cell adhesion [118]. Interestingly, it has been 
reported that PrPC inhibits Reelin-mediated shedding of contactin-associated protein 
Caspr from the cell surface, thus increasing its surface levels and potentiating the 
inhibitory effect of this protein on neurite outgrowth [119]. 
 
REELIN STRUCTURE AND PROCESSING 
 
The human RELN gene, located on the long arm of chromosome 7, was mapped and 
sequenced in 1997. This gene encodes for a large extracellular glycoprotein that 
consists of 3461 amino acids and has a predicted molecular weight of 388 kDa. Human 
Reelin is 94.2% identical to the mouse protein at the aminoacidic level, suggesting a 
strong functional conservation of the protein among species [120]. 
Reelin protein has a modular structure, composed by several domains (Figure 12) 
[121]. At the N-terminal region, a cleavable signal peptide of 27 amino acids is required 
for targeting the protein to the secretory pathway. The signal peptide is followed by a 
region of similarity with F-spondin, a protein secreted by floor plate cells that controls 
cell migration and neurite outgrowth. The N-terminal region of Reelin is prone to 
aggregation and presents a CR-50 epitope that can be recognized by CR-50 antibody, 
and is fundamental for Reelin-Reelin homophilic interactions. Indeed, it was shown 
that Reelin protein binds to each other to form a large protein complex, both in vitro 
and in vivo, and that this assembly formation is inhibited by CR-50 antibody [122]. 
Moreover, when the CR-50 region of Reelin is mutated, the protein fails to efficiently 
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activate downstream signalling cascade, meaning that Reelin exerts its physiological 
function by multimerization through this region [123]. The most striking feature of 
Reelin is the presence of eight internal repeats, so-called Reelin repeats (RR) that are 
composed of about 350 amino acids. Each repeat contains two related subdomains, A 
and B, and a central EGF-module enriched in cysteine residues [124]. At the C-terminal 
region of the protein is located a basic stretch of 33 amino acids, enriched in positively 
charged arginine residues, highly conserved among mammalian species and necessary 
for efficient activation of downstream signalling cascade [124, 125]. 
 
 
Figure 12. Domain structure of Reelin. Reelin contains a cleavable signal peptide at the amino terminus, 
followed by a region of similarity to F-spondin. The most striking feature of Reelin is the presence of a 
series of eight internal repeats comprising 350–390 amino acids (aa). These so-called Reelin repeats 
contain two related subdomains, A and B, separated by a stretch of 30 amino acids harbouring an 
epidermal growth factor (EGF)-like motif. A region rich in arginine residues at the carboxy terminus is 
required for secretion [121]. 
 
In vivo, Reelin is processed by cleavage in two sites located, respectively, between 
repeats 2 and 3  and between repeats 6 and 7.  This processing does not occur in  
Relnrl-Orl mutant mice, in which Reelin is not secreted, suggesting that the cleavage 
takes place after secretion. Moreover, the cleavage is inhibited by zinc chelators, 
suggesting that one or more metalloproteases are involved [126]. Indeed, more 
recently, three enzymes involved in Reelin processing have been identified: the serine 
protease tissue plasminogen activator (tPA) cleaves Reelin at its C-terminal site, the 
extracellular matrix metalloproteinase ADAMTS-4 and the disintegrin and 
metalloproteinase ADAMTS-5 are able to cleave Reelin at both N-terminal and C-
terminal sites [127]. As a result of the processing, Reelin is cleaved in five fragments 
that could be discriminated on molecular weight basis. Commonly used N-terminal 
antibodies allow detection of full-length Reelin and two smaller fragments, named N-
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R6 (about 300 kDa) and N-R2 (about 180 kDa) (Figure 13). Even though the 
physiological function of this processing is not fully understood, it has been reported 
that the central fragment of Reelin is necessary and sufficient to activate the 
downstream signalling cascade [128]. However, a more recent work shown that the N-
terminal cleavage of Reelin strongly impairs its signalling ability in comparison to the 
full-length protein [129]. 
 
 
Figure 13. Schematic representation of Reelin protein. The epitope of G10 antibody is shown (N-
terminal region of Reelin). The N-t and C-t cleavage sites are located after RR2 and RR6, respectively. RR; 
Reelin repeat [129]. 
 
REELIN SIGNAL TRANSDUCTION 
 
Reelin-signalling pathway is triggered by binding of Reelin to two transmembrane 
lipoprotein receptors, named apolipoprotein E receptor 2 (ApoER2), also known as 
low-density lipoprotein receptor-related protein 8 (LRP8), and very-low-density 
lipoprotein receptor (VLDLR) [130]. Reelin binds to its receptors in form of oligomers, 
promoting the clustering of receptors on the plasma membrane. Upon clustering, the 
intracellular adaptor protein Disabled-1 (Dab1) could be recruited by binding to NPxY 
motifs in the receptor tails and could be phosphorylated by Src family kinases, such as 
Src and Fyn, on five tyrosine residues (Tyr185, Tyr198, Tyr200, Tyr220, Tyr232) [131-
134]. Upon tyrosine phosphorylation, Dab1 is activated and can transduce the 
downstream signals. Among them, activated Dab1 could activate PI3K, leading to the 
activation of AKT, which in turn inhibits GSK3, the major kinase involved in the 
 36 
phosphorylation of microtubule-associated protein Tau [131, 135-137]. Indeed, Tau 
hyperphosphorylation is observed in mice in which Reelin pathway is disrupted [131]. 
Other downstream interactors of Dab1 are Crk-like protein (CRKL), which controls actin 
cytoskeleton rearrangements [138], and lissencephaly protein 1 (LIS1), which is 
involved in the regulation of neuronal migration and cortical lamination [139]. 
Finally, it has been shown that ApoER2 receptor could form a complex with 
postsynaptic density protein 95 (PSD95) and that this interaction is fundamental for 
the coupling between Reelin-signalling and NMDA receptors, and consequently for 
Reelin-mediated synaptic modulation [140, 141]. 
Reelin-signalling cascade is schematized in Figure 14 [117]. 
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Figure 14. Reelin-initiated signalling events in neurons. Reelin binds to lipoprotein receptors, VLDLR 
and ApoER2, with high affinity at the cell surface. Binding of Reelin to the receptors induces feed-
forward activation of Dab1, an adaptor protein that interacts with NPxY motifs in both receptor tails. 
The clustering of Dab1 activates Src family tyrosine kinases (SFKs), which potentiates tyrosine 
phosphorylation of DAB1. Phosphorylated Dab1 further activates phosphatidylinositol-3-kinase (PI3K) 
and subsequently protein kinase B (PKB). PKB activation inhibits the activity of glycogen synthase kinase 
3β (GSK3β). As a result, phosphorylation of tau protein (τ) is reduced, promoting microtubule stability. 
Tyrosine-phosphorylated (YP) Dab1 also recruits CRK-like (CRKL), which induces phosphorylation of a 
guanine nucleotide exchange factor, C3G122. Activated C3G promotes the formation of RAP1-GTP, 
which controls actin cytoskeleton rearrangement. Lissencephaly 1 (LIS1) is another binding partner of 
tyrosine-phosphorylated Dab1. It associates with α-subunits to form a Pafah1b complex, which 
regulates microtubule dynamics. Cyclin-dependent kinase 5 (CDK5) acts in parallel with Reelin on 
numerous substrates, including microtubules. p35 and p39 are activating subunits of CDK5. ApoER2 
associates with postsynaptic density protein 95 (PSD-95), an abundant scaffolding protein in the PSD, 
through an alternatively spliced exon. This interaction is crucial for the coupling of the Reelin-signalling 
complex to the NMDA (Nmethyl-d-aspartate) receptor (NMDAR). Reelin-activated SFKs tyrosine 
phosphorylate the NMDAR on NR2 subunits, resulting in the potentiation of NMDAR-mediated Ca
2+
 
influx. Elevated intracellular Ca
2+
 can activate the transcription factor cyclic AMP response element 
binding protein (CREB), thereby potentially initiating the expression of genes that are important for 
synaptic plasticity, neurite growth and dendritic spine development [117]. 
 38 
The majority of the signalling pathways present desensitization mechanisms that allow 
the cell to switch off the signal and to be ready to respond again to a repeated 
stimulation. Many evidences reported that Reelin-signalling pathway also displays a 
negative feedback mechanism. Indeed, disruption of the Reelin-signalling cascade (by 
genetic ablation of Reelin, VLDLR, ApoER2, or Fyn and Src) leads to the accumulation of 
Dab1 protein in vivo, while Dab1 mRNA expression is unchanged, suggesting the 
existence of a regulatory mechanism mediated by Dab1 downregulation [132, 133, 
142-145]. Dab1 downregulation is mediated by poly-ubiquitination and targeting to 
the proteasome, and this mechanism is dependent on Reelin-mediated tyrosine 
phosphorylation of Dab1 [146, 147]. Recently, Cullin 5 (Cul5) has been identified as the 
E3 ubiquitin ligase responsible for Dab1 poly-ubiquitination and degradation [148]. 
 
MOUSE MODELS OF REELIN-SIGNALLING DISRUPTION 
 
Developmental defects in neuronal migration are commonly found in neurological 
disorders. Currently, several mouse models of developmental brain disorders are 
available, and allowed the identification of genes involved in neural positioning and 
the study of the effects of their disruption [149]. 
Among them, the spontaneously arising mutant reeler mouse, in which Reelin 
expression is completely abolished, presents behavioural abnormalities, such as ataxia, 
tremors and reeling gaits [150]. The study of this mutant allowed the identification of 
the mouse Reelin protein [151]. Moreover, the study of the morphology of the mutant 
brain revealed cerebellar malformation, with severe hypoplasia, and disrupted laminar 
organization of cortical layers (Figure 15) [152]. Therefore, reeler mutation affects the 
positioning of neurons within specific layers, leading to abnormal migration of 
neurons, thus allowing to understand the fundamental role of Reelin in the correct 
organization of neurons in layered structures [152]. 
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Figure 15. Comparison of cerebellar, hippocampal and cortical morphology between normal (A, C, E) 
and reeler (B, D, F) mouse. A, B) Cerebellar morphology. Sagittal sections of the cerebellum of the 
normal (A) and reeler (B) mice are stained with cresyl violet. The size of the cerebellum of the reeler (A) 
is much reduced compared with the normal counterpart (B). A thin quasi-normal cerebellar cortex 
occupies the surface of the reeler cerebellum. Many malpositioned Purkinje cells are aggregated in the 
center of the reeler cerebellum, forming a central cellular mass (CCM). IC, inferior colliculus; SC, superior 
colliculus. Scale bar 1 mm. C, D) Hippocampal morphology. Horizontal sections of the hippocampus of 
the normal (C) and reeler (D) mice stained with cresyl violet. The distinct laminar structure of the 
hippocampus proper (i.e. Ammon’s horn) and dentate gyrus (DG) of the normal mouse (C) is disrupted 
in those of the reeler mouse (D). CA1–CA3, sectors 1–3 of Ammon’s horn; EC, entorhinal cortex; fh, 
hippocampal fimbria; Sub, subiculum. Scale bar 0.5 mm. E, F) Retrogradely labeled corticospinal tract 
(CST) neurons in the motor cortex of postnatal day 9 normal (E) and reeler (F) mice. CST neurons in the 
motor cortex are retrogradely labeled by injection of horseradish peroxidase (HRP) in the spinal cord 2 
days before death. HRP-labeled neurons are accumulated in layer V of the normal cortex (E), whereas 
they are scattered throughout the radial axis of the reeler cortex (F). Neutral red counterstaining. G, 
granular cell layer; I–VI, cortical layers of I–VI; LP, large pyramidal cell layer; MP + SP, medium and small 
pyramidal cell layer; PM, polymorphic cell layer; wm, white matter. Scale bar 100 μm [152]. 
 
 40 
As models of Reelin pathway disruption, ApoER2 and VLDLR knockout mice were 
generated by inserting a neomycin resistance cassette into the open reading frame of 
the two genes. Both ApoER2-/- and VLDLR-/- mice were born at the expected genetic 
ratio, appeared neurologically normal, with no signs of ataxia or other reeler 
phenotypes. On the contrary, double knockout mice (ApoER2-/-;VLDLR-/-) lacking the 
combination of these two receptors presented a typical reeler neurological phenotype 
characterized by progressive ataxia, reeling gaits and tremors. Histological analysis of 
mutant brains revealed strong disorganization of neurons in the hippocampus and in 
the cerebellum, that appeared in a rudimentary form, completely lacking its foliation 
(Figure 16). Indeed, both receptors can compensate for each other to a certain extent, 
since only the lack of both receptors causes the reeler phenotype, while the loss of 
ApoER2 or VLDLR alone causes only subtle but distinguishable phenotypes [144]. 
 
 
Figure 16. Histologic analysis of hippocampus and cerebellum of wild-type and VLDLR
-/-
, ApoER2
-/-
 and 
double mutant mice. Hematoxylin/eosin-stained sagittal sections of hippocampus at 43 (a, d, g, and j) 
and cerebellum at 2.53 (b, e, h, and k) relative magnification of P20 wild type (a, b), VLDLR
-/-
 (d, e), 
ApoER2
-/-
 (g, h), and double knockout (j, k) are shown. Arrows in (d) and (g) point at the split in the CA1 
region, which is also a characteristic feature in reeler and mDab1-deficient mice. The arrow in (k) points 
to the small rim of dysplastic granule cells in the double knockout [144]. 
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Scrambler mouse is a spontaneously arising mutant that appeared in 1991 and 
exhibited a phenotype identical to reeler mouse [153]. Moreover, the scrambler 
mutation resulted in a loss of lamination in the cortex, hippocampus and cerebellum 
that is indistinguishable from that observed in the reeler mouse [154, 155]. Another 
mouse mutant, the yotari mouse, was also described as phenotypically 
indistinguishable from the reeler mouse [156]. Both scrambler and yotari mutants arise 
from mutations in mdab1 gene and express little or no Dab1 protein [142]. The reeler 
phenotype and the impairment in cortical, hippocampal and cerebellar layering is also 
observed in mdab1 knockout animals [157]. Indeed, the similar phenotypes of reeler, 
scrambler, yotari and mdab1 null mice suggest that Reelin and Dab1 function as 
signalling molecules that play a fundamental role in neuronal positioning [142]. 
Finally, disruption of both Src and Fyn kinases resulted in a phenocopy of the reeler 
phenotype, with impaired layering organization of neurons [145]. 
 
REELIN EXPRESSION AND BIOLOGICAL FUNCTIONS 
 
During embryogenesis, Reelin is highly expressed by Cajal-Retzius neurons, located at 
the marginal zone of the developing neocortex. Already in the prenatal period, Reelin 
gene expression could be detected in the olfactory bulb, striatum, ventral 
telencephalon, hypothalamus, thalamus and pretectum [158]. Even though Cajal-
Retzius neurons disappear after birth, Reelin expression is maintained also in 
adulthood. In particular, Reelin is strongly expressed by cortical GABAergic 
interneurons, with the highest levels in layers I and V. In the hippocampus, Reelin is 
expressed by interneurons present in the stratum oriens and stratum radiatum. 
Moreover, Reelin expression could also be detected in the cerebellar granule cells, 
mitral cells of the olfactory bulb and in some areas of the hypothalamus, striatum and 
superior colliculus [117]. 
 
Prenatally, Reelin is expressed by the Cajal-Retzius neurons of the developing 
neocortex. These neurons migrate a short distance toward the marginal zone, where 
they form the pial surface of the cortex [159]. Later born neurons migrate from the 
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ventricular zone towards the pial surface and, as they reach the marginal zone, they 
receive a stop signal from Reelin [160]. Through this inside-out mechanism, the 
formation of organized cortical layers take place [161]. Reelin is fundamental for the 
correct organization of neurons in layered structures, such as cortex, hippocampus and 
cerebellum. Indeed, the absence of Reelin expression in the reeler mouse leads to 
impaired cortical and cerebellar lamination, as the neurons fail to acquire their proper 
layer position [151, 152]. 
Reelin expression is maintained during adulthood; therefore this protein should play a 
physiological role also postnatally. Indeed, a direct influence on synapses have been 
reported, being able to modulate synaptic plasticity, hippocampal-dependent learning 
and memory processes [117]. 
 
ROLE IN DISEASES 
 
Altered Reelin pathway plays a role in the pathogenesis of neurodevelopmental and 
neuropsychiatric disorders, such as schizophrenia, autism and bipolar disorder. Indeed, 
Reelin expression is reduced by hypermethylation of the RELN gene in schizophrenia 
and autism. Moreover, a link between Reelin pathway and epilepsy and pain sensitivity 
has been observed [117]. Finally, disruption of the RELN gene in humans is responsible 
of lissencephaly (reduction in the number of brain convolutions) with cerebellar 
hypoplasia, severe ataxia, epilepsy and cognitive delay [162]. 
 
REELIN/DAB1 SIGNALLING IN ALZHEIMER’S DISEASE 
 
Many evidences point to an involvement of Reelin pathway in Alzheimer’s disease 
pathogenesis and progression. Indeed, tau protein resulted hyperphosphorylated in 
mouse models in which Reelin pathway is disrupted [131, 163, 164]. Moreover, a 
reduced expression level of Reelin accelerates A deposition [164]. Viceversa, in vitro 
treatment with A impairs Reelin signalling [165]. Finally, Reelin is able to interact with 
APP and, in vitro, with A, while APP also interacts with ApoER2 and Dab1 [166-171]. 
These findings reveal that Reelin and the components of its signalling cascade may 
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influence APP processing and, viceversa, APP may influence Reelin-signalling [172]. 
Indeed, it has also been shown that APP cytosolic domain may bind Dab1, retaining it 
in the cytoplasm and thus impairing Reelin signalling [173]. Besides, Reelin receptors 
may bind apolipoprotein E (ApoE) that could impair Reelin signalling by competing 
with Reelin for the binding [130, 131]. Finally, it has been shown that apolipoprotein J, 
also known as clusterin, is a ligand for Reelin receptors which is able to trigger the 
same signalling cascade [174]. Interestingly, many evidences reported an important 
role of clusterin in both AD and prion diseases [175-178].  
The progression of AD may influence Reelin-signalling and, viceversa, alterations in 
Reelin pathway and its components may contribute to neuronal dysfunction and 
disease progression [172]. 
Despite many efforts were done, still no consensus on Reelin expression levels during 
AD has been reached [172]. However, Reelin processing is thought to play an 
important role in the disease, as dysfunction of Reelin proteolysis in post-mortem AD 
tissues has been reported [179]. Indeed, increased levels of N-R2 fragment have been 
observed in AD and frontotemporal dementia patients [180, 181]. 
Interestingly, Dab1 is able to interact with APP altering its processing and intracellular 
trafficking. Indeed, it has been shown that Dab1 increases cell surface expression of 
APP, increases its -cleavage and decreases A production [182]. Recently, it has been 
shown that this effect of Dab1 is mediated by Fyn kinase, which promotes the 
localization of both APP and Dab1 in the lipid rafts [183, 184]. 
 
REELIN/DAB1 SIGNALLING IN PRION DISEASES 
 
Interestingly for the present work, despite the role of Dab1 in prion diseases has not 
been deeply investigated, it has been reported that APP processing and β-amyloid 
deposition in sporadic Creutzfeldt-Jakob patients are dependent on Dab1. In particular, 
a direct correlation between Dab1 phosphorylation, Aβ deposition and PrPSc type in 
human sCJD has been shown. In PrPSc type 1 patients increased Dab1 phosphorylation 
and lower β C-terminal fragment (CTF) production, with absence of Aβ deposition, 
were observed, while PrPSc type 2 patients were charactherized by lower levels of 
Dab1 phosphorylation, βCTF production and relevant Aβ deposition [185]. 
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AIM OF THE PROJECT 
 
Prion diseases are a group of rare, fatal and progressive neurodegenerative disorders 
affecting both humans and animals. Among neurodegenerative diseases, prion 
disorders are of prominent biological and pathological interest since they may present 
with genetic, sporadic and infectious origin. The cellular form of the prion protein 
(PrPC), which is endogenously encoded by the Prnp gene, has been widely investigated 
since its misfolded isoform (scrapie prion protein, PrPSc), enriched in β-sheets and 
prone to aggregation, is the causative agent of prion diseases [2, 37]. The pathogenesis 
of prion diseases, and the nature of the neurotoxicity observed in these disorders, is 
currently under debate, as they could be gain of toxic function consequences of the 
formation of PrPSc, or could be due to the loss of the normal physiological function of 
PrPC [4]. According to the gain of toxic function hypothesis, the misfolded protein 
acquires novel toxic functions and, therefore, is able to trigger direct neurotoxicity [14, 
15, 38]. However, PrPSc alone is not sufficient to induce prion disease [16-18]. 
Therefore, it has been proposed that the loss of a critical physiological function of PrPC 
may cause neurodegeneration [38]. However, genetic ablation of Prnp expression 
causes subtle phenotypic effects and does not induce neurodegeneration by itself [19, 
20], thus arguing against the loss-of-function hypothesis. Indeed, multiple mechanisms 
may contribute to the pathology of prion diseases, leading to progressive 
neurodegeneration. 
For this reason, a better definition of the exact physiological function of PrPC 
represents a critical challenge of the prion field, that may help to better understand 
pathogenetic mechanisms underlying neurodegeration, as well as to propose new 
therapeutic strategies. Despite many efforts have been done in the past years, PrPC 
physiological function has not been completely defined. However, it has been 
suggested that PrPC, which is mostly abundant in the nervous system, plays a role in 
neurite outgrowth, neuronal survival, synapse formation and function, and in the 
maintenance of myelinated axons [21]. Importantly for the present work, it has been 
reported that PrPC also plays a fundamental role in modulating cell signalling, acting as 
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a dynamic scaffold for the assembly of many different signalling molecules at the 
neuronal surface [38, 68, 69]. Indeed, PrPC directly interacts with NCAM at neuronal 
surface, thus regulating Fyn kinase activity [74]. Moreover, PrPC could affect PI3K and 
Akt/PKB activity [100, 103]. Finally, more recently, it has also been shown that PrPC 
induces GSK3β inactivation in a caveolin/Lyn-dependent fashion [95]. All these 
intracellular kinases could be also regulated by yet another protein, Reelin, an 
extracellular matrix glycoprotein that activates a linear downstream signalling pathway 
[117]. 
Interestingly, it has been reported that Reelin-signalling pathway is involved in both 
Alzheimer’s and prion diseases. Indeed, the intracellular adaptor protein Dab1 is able 
to affect APP processing and intracellular trafficking, increasing cell surface expression 
of APP and its -cleavage and decreasing A production [182]. Moreover, Dab1 has 
been shown to influence amyloid beta deposition in sporadic Creutzfeldt–Jakob 
disease [185]. 
 
In light of these considerations, this thesis is aimed to investigate the functional 
interaction between the prion protein and the Reelin/Dab1 signalling cascade from a 
physiological and a pathological point of view. 
Taking advantage of Prnp knockout mice (Prnp0/0) and wild-type (Prnp+/+) littermates, 
expression and activation state of different components of the Reelin/Dab1 signalling 
pathway were evaluated in mouse brains during early postnatal days (postnatal day 4 
(P4)). To better investigate the effects of PrPC absence on Dab1 activation in response 
to Reelin, an ex vivo model based on primary cortical neurons obtained from Prnp0/0 
and Prnp+/+ embryos was used. 
Viceversa, we took advantage of different mouse models of Reelin-signalling 
disruption to investigate the effects of signalling ablation on PrPC. Indeed, PrPC 
expression was evaluated in mouse brains of different genotypes at postnatal day 4. 
Moreover, prion-infected mice were used as prion pathology model and the 
expression of different components of the Reelin/Dab1 signalling pathway was 
evaluated in brains obtained from terminally sick animals. 
Finally, Dab1 gene expression was evaluated in human samples obtained from 
sporadic Creutzfeldt–Jakob disease patients. 
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MATERIALS AND METHODS 
 
HUMAN SAMPLES 
 
Postmortem human brain samples were derived from four sCJD type 1 patients, four 
sCJD type 2 patients and four healthy controls. Frontal cortex of each subject was 
collected and immediately frozen in liquid nitrogen. In parallel, whole blood from two 
symptomatic sCJD patients and two healthy controls were collected in PAXgene Blood 
RNA tubes. Samples were then processed for RNA extraction and gene expression 
analysis as described below. 
 
ANIMALS 
 
Inbred FVB/N Prnp+/+ and littermates FVB Prnp0/0 mice were used as a model for PrPC 
depletion. The FVB Prnp0/0 were obtained by backcrossing the original Zurich I Prnp0/0 
mice [19] to FVB/N inbred mice for more than 20 generations [186]. Genotypes were 
confirmed by PCR analysis as described [187]. The day of birth was considered as 
postnatal day (P) 0. Sex-matched P4 animals were sacrificed by decapitation, brains 
were extracted, immediately frozen in liquid nitrogen and stored at -80°C for further 
applications. 
For neuronal primary cultures, FVB Prnp+/0 pregnant mice were used. The day of 
vaginal plug detection was considered as embryonic day (E) 0. At E16, the pregnant 
females were sacrificed with CO2 and the embryos were extracted by caesarean cut 
and further processed for cultures preparation. Genotypes were confirmed by PCR 
analysis as described [187]. 
Reeler mutant mice, ApoER2-/-, VLDLR-/-, ApoER2-/-/VLDLR-/- and Dab1-/- mice were used 
as model for Reelin pathway disruption. Littermates wild-type were used as controls. 
For what concern ApoER2-/-/VLDLR-/- double knockout mice, VLDLR-/- littermates were 
used as controls. The animals were on a C57BL/6JxSv129Ev mixed background. 
Genotypes were confirmed by PCR analysis. P4 animals were sacrificed by 
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decapitation, brains were extracted and dissected to obtain 4 samples from each 
animal: brain hemisphere, cortex, hippocampus and cerebellum. Samples were 
immediately frozen in liquid nitrogen and stored at -80°C. 
Age and sex-matched CD1 mice (Crl:CD1(ICR) strain code 022, charles river) were used 
for prion infection experiments. Adult animals were sacrificed with CO2, brains were 
extracted, immediately frozen in liquid nitrogen and stored at -80°C. 
All experiments were performed in accordance with European regulations [European 
community Council Directive, November 24, 1986 (86/609/EEC)] and were approved 
by the local authority veterinary service. All efforts were made to minimize animal 
suffering and to reduce the number of animals used. 
 
INTRACEREBRAL INOCULATION OF PRIONS 
 
Rocky Mountain Laboratory (RML) prion infected brain homogenate was prepared at a 
10% w/v in phosphate-buffered saline (PBS). 
For the first set of experiments, 20 μL of 10% brain homogenate was stereotactically 
injected in the striatum of 2-months old outbred CD1 mice (n = 5). Not inoculated age- 
and sex-matched CD1 mice were used as control (n = 5). Inoculated mice were 
monitored daily for clinical signs of prion disease. All the animals were sacrificed at the 
terminal stage of prion infection. 
For the second set of experiments, 2.5 μL of 10% brain homogenate was 
stereotactically injected in the hippocampus of 2-months old outbred CD1 mice (n = 
16). Not inoculated age- and sex-matched CD1 mice were used as control (n = 16). Pre-
symptomatic animals (n = 8) were sacrificed 97 days post inoculation (d.p.i.). Terminal 
stage animals (n = 8) were monitored daily for clinical signs of prion disease and were 
sacrificed at the end stage of clinical prion disease. 
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PRIMARY NEURONAL CULTURES PREPARATION 
 
Mouse embryonic cortical neurons were isolated and cultured as previously described 
[188], with some modifications. E16 embryos were collected from FVB Prnp+/0 
pregnant females. Cerebral hemispheres were dissected under sterile conditions. 
Briefly, the cortices were separated from the midbrain and the meninges were 
stripped off. Cortices from each embryo were incubated in 2 mL of 0.05% Trypsin-EDTA 
(Gibco) supplemented with 10mM MgCl2 and 0.05 mg/mL DNaseI (Roche), for 10 min 
at 37°C and 10 min at RT. The tissue was then homogenized by pipetting in 1 mL of 
neuron growth media [Neurobasal Medium (Gibco) containing 10% B27 supplement 
(Gibco), 1% Penicillin-Streptomycin (Gibco), 1% Glutamax (Gibco)] supplemented with 
0.1 mg/mL DNaseI. Following centrifugation at 100 g for 5 min, pellets were 
resuspended in 1 mL of neuron growth media and neurons were plated on dishes pre-
coated overnight a 37°C with poly-L-ornithine 0.05 mg/mL (Sigma-Aldrich). The 
neurons were allowed to differentiate for 5 days in vitro (DIV) and were then treated 
as described below. After stimulation, cells were lysed and processed for Western Blot 
(WB) analysis. To detect Reelin secreted by neurons under basal conditions, neuron 
growth media was collected after 5 DIV, filtered using 0.22 m filters (Millipore) and 
stored at -80°C. Total protein content was measured using  bicinchoninic acid (BCA) 
assay (Sigma-Aldrich). Reelin content was then evaluated through WB analysis loading 
onto a 4-12% precast gradient gel (NuPAGE™ Novex™ 4-12% Bis-Tris Midi Protein Gels, 
Invitrogen) the same total protein amount for each sample. 
 
PRODUCTION OF REELIN-CONDITIONED SUPERNATANT 
 
Reelin-containing supernatants and control supernatants were prepared as previously 
described [189]. Brefly, HEK-293T cells stably transfected with the expression plasmid 
pCrl encoding full-length mouse Reelin [122] and control cells transfected with an 
empty vector (mock) were grown in DMEM (Gibco) supplemented with 10% fetal 
bovine serum (FBS, Gibco), 1% Penicillin-Streptomycin and 0.9 g/L G418 (Geneticin, 
Gibco) for 2 days to subconfluency. Cells were switched to serum-free DMEM + 1% 
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Penicillin-Streptomycin and grown for 2 days at 37°C in 5% CO2. Conditioned medium 
was then collected and concentrated 10-fold using 100 kDa cut-off centrifugal filters 
(Millipore), sterile-filtered (0.22 m filters, Millipore), aliquoted and stored at −80°C 
until used. Reelin content was analysed by WB using anti-Reelin G10 monoclonal 
antibody (see Table 5). 
 
PRODUCTION OF RECOMBINANT MOUSE FULL-LENGTH PrP 
(recMoPrP) 
 
Full-length MoPrP(23-231) was cloned, expressed and purified according to our 
previous protocols [190, 191]. The purified protein was prepared in sterile phosphate-
buffered saline (PBS) for neuronal cultures treatment at a concentration of 0.25 
mg/mL, equivalent to 10 M concentration. The quality of the protein was confirmed 
by SDS/PAGE analysis followed by WB using an anti-PrP primary antibody (see Table 5). 
 
PRODUCTION OF RECOMBINANT MOUSE PrP-hFc FUSION PROTEIN 
(moPrP-hFc) 
 
For mouse PrP-hFc fusion protein production, the sequence encoding the extracellular 
portion of mouse PrP was amplified by PCR using the forward primer 5’-
ATAGAATTCAATGAAAAAGCGGCCAAAGCCTG-3’ and the reverse primer 5’-
ATAGAATTCACGCTGGATCTTCTCCCGTCGTAA-3’ (including EcoRI restriction site). This 
fragment was cloned into the expression vector pFUSE containing the Fc portion of 
human IgG1. The mouse PrP-hFc fusion protein was produced by transient transfection 
in HEK293T cells. The supernatant containing PrP-hFc protein was purified using AKTA-
prime and prepacked protein A Sepharose column. The quality of the protein was 
confirmed by SDS/PAGE analysis followed by Coomassie staining or by WB using an 
anti-PrP primary antibody (see Table 5). 
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PRIMARY NEURONAL CULTURES STIMULATION WITH REELIN, 
recMoPrP AND PrP-hFc 
 
Reelin stimulation of neuronal cultures was performed as previously described [133], 
with some modifications. After 5 DIV, cortical neurons were stimulated with mock- or 
Reelin-conditioned medium diluted 10-fold in the neuron growth media for 15 min at 
37°C in 5% CO2. 
Stimulation of primary cultures with recombinant full-length MoPrP(23-231) was 
performed as described in literature [91], adjusting the published protocol to our 
experimental setup. After 5 DIV, cortical neurons were stimulated with 1 M or 2 M 
of recMoPrP diluted in the neuron growth media for 20 min at 37°C in 5% CO2. PBS 
treatment (vehicle only), under the same conditions, was used as negative control. 
Stimulation of primary cultures with purified PrP-hFc protein has been performed 
adapting a published protocol to our setup [74]. After 5 DIV, cortical neurons were 
stimulated with 2 g/mL of protein diluted in the neuron growth media for 20 min at 
37°C in 5% CO2. Control neurons were treated with purified human Fc (hFc) or with a 
purified unrelated fusion protein (RAE-1-hFc) under the same conditions. 
 
PRIMARY NEURONS LYSATES PREPARATION 
 
After treatment, cells were washed in PBS and lysed in CHAPS buffer (50mM Tris-HCl, 
pH 7.5, 150mM NaCl, 1mM EDTA, 0.5% CHAPS, 10% glycerol) supplemented with 
protease inhibitor cocktail (complete mini EDTA-free protease inhibitor cocktail, 
Roche) and phosphatase inhibitors [5mM Na3VO4, 0.5mM NaF, phosphatase inhibitor 
cocktail 2 and 3 (Sigma-Aldrich)]. Samples were cleared by centrifugation at 10000rpm 
for 10min at 4°C, supernatants were collected and total protein concentration was 
measured using BCA assay. Samples were then stored at -20°C before being processed 
for WB analysis. 
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TISSUE HOMOGENIZATION FOR PROTEIN EXTRACTION 
 
Brains from Prnp0/0 and Prnp+/+ mice were homogenized in CHAPS buffer 
supplemented with protease inhibitor cocktail (complete mini EDTA-free protease 
inhibitor cocktail, Roche) and phosphatase inhibitors [5mM Na3VO4, 0.5mM NaF, 
phosphatase inhibitor cocktail 2 and 3 (Sigma-Aldrich)]. Brains from prion-inoculated 
mice were homogenized in PBS supplemented with protease inhibitor cocktail. After 
homogenization, samples were left on a rotating wheel at 4°C for 30 minutes to allow 
the complete lysis, sonicated for 30 seconds using a probe-type sonicator and cleared 
by centrifugation (10000rpm, 10min, 4°C). Supernatants were collected and total 
protein concentration was measured using BCA assay. Samples were stored at -20°C 
for further applications. 
 
BIOCHEMICAL ANALYSIS OF BRAIN HOMOGENATES AND 
NEURONAL LYSATES 
 
Protein expression was analysed using WB technique. The same total amount of 
protein (15-30 g) for each sample was loaded onto a Tris-Glycine SDS-PAGE gel for 
protein separation, after denaturation at 95°C for 5 min in 2X loading buffer (0.1 M 
TrisHCl pH 6.8, 4% SDS, 20% glycerol, 8 M Urea, 0.2 M DTT, 0.004% bromophenol 
blue). Different acrylamide percentage gels were used depending on the molecular 
weight of analysed proteins. Proteins were then transferred onto a nitrocellulose 
membrane (GE Healthcare). The membranes were blocked with 5% non-fat milk in 
TBST (Tris-Buffered Saline, 0.1% Tween-20) or with 5% bovine serum albumin (BSA) in 
PBST (Phosphate-Buffered Saline, 0.1% Tween-20) for 1 hour at RT. Overnight 
incubation at 4°C with primary antibodies followed (see Table 5). After the incubation 
for 1 hour at room temperature (RT) with secondary antibody horseradish 
peroxidase(HRP)-conjugated diluted in blocking solution, the signal was detected using 
enhanced chemiluminescent system (ECL, Amersham Biosciences) and recorded with 
the digital imaging system Alliance 4.7 (UVITEC, Cambridge, UK). Densitometric 
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analysis was performed using Uviband Analysis Software 15.0 (UVITEC, Cambridge, 
UK). 
For non-phosphorylated proteins, the signals were normalized against -Actin or -III-
Tubulin. For phosphorylated proteins, the membranes were developed twice in order 
to detect on the same immunoblot both the phosphorylated and, subsequently, the 
total protein (non-phosphorylated plus phosphorylated). After the detection of the 
phospho-protein, the membrane was incubated with 0.01% sodium azide in 5% non-
fat milk in TBST for 3 hours at RT. Following several washes, the membrane was then 
incubated overnight at 4°C with the primary antibody against the total protein, and 
developed as described above. The signal of the phosphorylated protein was then 
normalized on the signal of the total protein. 
 
IMMUNOPRECIPITATION OF DAB1 FROM BRAIN HOMOGENATES 
 
Immunoprecipitations experiments were carried out using the PureProteome Protein 
A Magnetic Bead System (Millipore). Three hundred micrograms of total protein 
extracts were incubated with 2 μg of anti-Dab1 antibody (H-103, Santa Cruz 
Biotechnologies), or with 2 μg of normal rabbit IgG (12-370, Millipore) as control, for 2 
hours at 4°C on a rotating wheel. Fifty microliters of the beads suspension were used 
for each sample. The pre-formed antibody-antigen complex was added to the beads 
and then incubated for 2 hours at 4°C on a rotating wheel. The beads were then 
extensively washed with PBS + 0.1% Tween 20 and resuspended in 40 μL of 2X loading 
buffer. After 5 min boiling at 95° C, samples were subjected to standard 
immunoblotting procedures, as described above. On the same membrane used to 
detect immunoprecipitated protein, 30 μg of starting material (input) were loaded. 
The signal of the phosphorylated protein was detected using anti-phosphotyrosine 
4G10 antibody (Millipore), while anti-Dab1 antibody (Abcam) was used to detect the 
signal of the total protein (see Table 5). 
Dab1 expression was measured performing the ratio between immunoprecipitated 
Dab1 and the starting amount of protein present in the input material. The amount of 
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phosphorylated Dab1 was normalized on total Dab1 signal. Data are expressed as ratio 
between Prnp0/0 and Prnp+/+ mice  standard error. 
 
CO-IMMUNOPRECIPITATION EXPERIMENTS 
 
Co-immunoprecipitation experiments were carried out applying four different 
protocols (described here following the presenting order of the results). 
In the first approach (see Figure 19a), 30 l of Protein A/G-Sepharose (GE Healthcare) 
were incubated with 1 ml of anti-PrP W226 hybridoma cell supernatant overnight at 
4°C on a rotating wheel. As negative controls, 14F2 anti-DISC1 antibody and protein-
free hybridoma medium (PFHM, Gibco) were used. After removing the supernatant, 
two washes in TBS (Tris-Buffered Saline) + 0.3% Sarcosyl were performed. Prnp+/+ brain 
sample was processed in CHAPS buffer, as described above (without sonication step), 
to obtain a 10% w/v brain homogenate, that is then diluted to 1% w/v in TBS + 0.3% 
Sarcosyl. 1 ml of 1% brain homogenate was incubated with the preformed antobody-
bead complex overnight at 4°C on a rotating wheel. The day after, the resin was firstly 
washed in ice-cold IP1 buffer (50 mM Tris-HCl pH=7.5, 150 mM NaCl, 1% NP-40, 0.5% 
DOC), then in ice-cold IP2 buffer (50 mM Tris-HCl pH=7.5, 0.5 M NaCl, 0.1% NP-40, 
0.05% DOC) and finally in ice-cold IP3 buffer (50 mM Tris-HCl pH=7.5, 0.1% NP-40, 
0.05% DOC). The beads were then resuspended in 30 μL of 2X loading buffer. After 5 
min boiling at 95° C, samples were subjected to standard immunoblotting procedures, 
as described above. On the same membrane used to detect immunoprecipitated 
proteins, 20 μL of starting material (input) were loaded. To perform the reverse 
experiment, immunoprecipitation of Reelin or ApoER2 were performed following the 
same protocol using 3 μg of anti-Reelin or anti-ApoER2 antibody, respectively. In these 
cases, normal mouse IgG (12-371, Millipore) or normal rabbit IgG (12-370, Millipore), 
respectively, were used as negative control. 
The second approach used is based on a published protocol [74] with some 
modifications (see Figure 19b). Prnp+/+ brain homogenates were prepared in 50 mM 
Tris-HCl buffer (pH 7.5), containing 0.32 M sucrose, 1 mM CaCl2, 1 mM MgCl2, and 1 
mM NaHCO3. Samples containing 1 mg of protein were then lysed for 30 min in 50 mM 
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Tris-HCl buffer (pH 7.5), containing 150 mM NaCl, 0.5% Triton X-100, 1% β-octyl-d-
glucopyranoside, 1 mM sodium fluoride, 2 mM NaVO4, 0.1 mM PMSF, and EDTA-free 
protease inhibitor cocktail (Roche). Samples were then centrifuged for 15 min at 
20,000 g and 4°C. Supernatants were incubated with 3 μg of anti-Reelin or anti-ApoER2 
antibody, or with normal mouse IgG or normal rabbit IgG, respectively, as negative 
control, overnight at 4°C on a rotating wheel. Precipitation with 30 μL of Protein A/G-
Sepharose beads for 3 h at 4°C followed. The beads were then washed three times 
with RIPA buffer (150 mM NaCl, 1.0% NP-40, 0.5% DOC, 0.1% SDS, 50 mM Tris-HCl 
pH=8.0) and once with PBS. The beads were then resuspended in 30 μL of 2X loading 
buffer. After 5 min boiling at 95° C, samples were subjected to standard 
immunoblotting procedures, as described above. On the same membrane used to 
detect immunoprecipitated proteins, 20 μL of starting material (input) were loaded. 
In the third protocol (see Figure 19c), 1 ml of 1% w/v Prnp+/+ brain homogenate 
prepared in CHAPS buffer, as described above (without sonication step) was incubated 
overnight at 4°C with 3 μg of anti-Reelin or anti-ApoER2 antibody, or with normal 
mouse IgG or normal rabbit IgG, respectively, as negative control. Precipitation with 30 
μL of Protein A/G-Sepharose beads for 3 h at 4°C followed. The beads were then 
washed three times with CHAPS buffer and resuspended in in 30 μL of 2X loading 
buffer. After 5 min boiling at 95° C, samples were subjected to standard 
immunoblotting procedures, as described above. On the same membrane used to 
detect immunoprecipitated proteins, 20 μL of starting material (input) were loaded. 
Finally, protein crosslinking was applied to brain samples, following manifacturer’s 
instruction, before proceding with immunoprecipitation (see Figure 20). Briefly, Prnp+/+ 
brain sample was homogenized in PBS supplemented with 1 mM MgCl2 and 0.1 mM 
CaCl2, lysed for 40 minutes at 4°C on a rotating wheel and cleared by centrifugation 
(16000rcf, 10 min, 4°C). 1 ml of supernatant was then incubated with 30 μL of 20 mM 
DSP (dithiobis[succinimidyl propionate], ThermoScientific) for 30 minutes at RT on a 
rotating wheel (protected from light). 50 μL of 1M Tris pH=7.5 were added and the 
sample was then incubated 15 minutes at RT on a rotating wheel. Following 
centrifugation (21000rcf, 20min, 4°C), the pellet was resuspended in 800 μL of CHAPS 
buffer supplemented with protease and phosphatase inhibitors. After adding 50 μL of 
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SDS 1%, the sample was subjected to a brief sonication. Finally, immunoprecipitation 
was performed following the third protocol described above. 
 
ANTIBODIES 
 
Primary and secondary antibodies against non-phosphorylated proteins were diluted 
in 5% non-fat milk in TBST, while antibodies against phosphorylated proteins were 
used in 5% BSA in PBST. All the primary antibodies used in the present work are 
reported in Table 5. Secondary antibodies, goat anti-mouse and goat anti-rabbit HRP-
conjugated, were from DAKO and were diluted 1:2000 in blocking solution. Secondary 
antibody goat anti-human HRP-conjugated (ThermoScientific) was diluted 1:5000 in 
blocking solution. To avoid immunoglobulin detection, Mouse TrueBlot ULTRA 
(diluted 1:30000) and Rabbit TrueBlot (diluted 1:10000) secondary antibodies 
(Rockland Laboratories) were used to visualize Fyn and Dab1 signal, respectively, in 
mouse brains in standard WB (for Fyn kinase) or after immunoprecipitation (for Dab1). 
 
TARGET ANTIBODY COMPANY/REFERENCE DILUTION 
Reelin 
Mouse monoclonal G10 
 
Millipore 1:1000 
Reelin Mouse monoclonal 20E12 Prof. Korth’s laboratory IP 
DISC1 Mouse monoclonal 14F2 Prof. Korth’s laboratory IP 
ApoER2 Rabbit monoclonal [EPR3326] Abcam 1:1000 
VLDLR Mouse monoclonal 6A6 Millipore 1:1000 
Dab1 Rabbit monoclonal [EP2248Y] Abcam 1:1000 
Dab1 Rabbit polyclonal H-103 Santa Cruz Biotechnology 1:500 
Phospho-Tyrosine Mouse monoclonal 4G10 Millipore 1:1000 
Fyn Rabbit monoclonal 04-343 Millipore 1:2000 
Fyn Mouse monoclonal (FYN-59) Santa Cruz Biotechnology 1:1000 
Phospho-Src family (Tyr416) Rabbit polyclonal 2101S Cell Signalling Technologies 1:1000 
NCAM Rabbit polyclonal AB5032 Chemicon International 1:1000 
AKT Rabbit polyclonal 9272 Cell Signalling Technologies 1:1000 
Prion protein 
Humanized D18 antibody 
fragment (Fab) 
[192] 1:1000 
Prion protein Mouse monoclonal W226 [193] 1:1000 
Table 5. List of the primary antibodies used for immunoblotting. 
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RNA EXTRACTION FROM BRAIN SAMPLES AND REAL-TIME PCR 
 
In order to evaluate the expression of Dab1 gene, total RNA was extracted from brain 
samples of sex-matched P4 mice. Two independent sets of samples were analized: four 
Prnp0/0 and four Prnp+/+ females, and four Prnp0/0 and four Prnp+/+ males. 
For prion-infected samples, RNA was extracted from brains of four animals for each 
group: WT controls of 5 months of age, WT controls of 7 months of age, RML-infected 
mice 3 months post-inoculation and RML-infected mice at the terminal stage of 
infection. 
One brain hemisphere for each sample was homogenized in TRIzol reagent (Invitrogen) 
and total RNA was extracted following manufacturer’s instructions. Samples were 
treated with RNase-free DNase set (Qiagen) to reduce DNA contamination, and then 
purified with RNeasy mini kit (Qiagen). RNA quantification was performed using 
NanoDrop 2000 spectrophotometer (Thermo Scientific) and RNA quality was evaluated 
through agarose gel electrophoresis. Besides, integrity of the 18S and 28S ribosomal 
bands was assessed by capillary electrophoresis using the 2100 Bioanalyzer (Agilent 
Technologies). 
Retrotranscription of 4 g of RNA was performed using SuperScriptIII RT (Invitrogen) 
and oligo-dT primer (5’-GCT GTC AAC GAT ACG CTA CGT AAC GGC ATG ACA GTG(T)24-
3’). In parallel, for each sample a non-retrotranscribed negative control (-RT) was 
prepared by omitting the enzyme in the reactions in order to evaluate genomic DNA 
contamination. 
Expression analysis of targets of interest by quantitative reverse transcription real-time 
PCR (RT-qPCR) was performed using gene-specific primer pairs. All primers used for RT-
qPCR are listed in Table 6. The specificity of each couple of primers for the intended 
target gene was verified through non-quantitative PCR followed by agarose gel 
electrophoresis. RT-qPCR was carried out using 2X iQTM SYBR Green Supermix (Bio-
Rad  Laboratories, Inc.) and 400 nM of forward and reverse primers (Sigma-Aldrich) on 
an iQ5 Multicolor Real-Time PCR Detection System (Bio-Rad  Laboratories, Inc.). A 
starting amount equivalent to 1 ng of RNA was used for each reaction. After initial 
denaturation for 3 min at 95°C, 40 cycles were performed at 95°C for 15 seconds and 
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60°C for 1 min. -RT controls were included in the plates for each primer pair and 
sample. The expression of the target genes was normalized on the expression of two 
housekeeping genes: -Actin and -III-Tubulin. The relative expression of each gene of 
interest versus the housekeeping gene chosen as reference was calculated using the 
ΔΔCT method [194]. Significance was calculated with unpaired student t-test (p-
value < 0.05). 
For what concern mdab1 gene transcription, three murine Dab1 mRNA isoforms 
encoding proteins of 555, 217, and 271 residues have been described. Dab217 mRNA 
differs from the Dab555 mRNA by a consensus splice donor sequence, encodes a 
further 18 residues before a stop codon, and terminates with a 3’-UTR that is different 
from Dab555. Dab271 mRNA contains an additional exon that encodes 30 residues 
before a stop codon [147]. Indeed, to quantify Dab1 mRNA expression we used two 
couples of primers published in literature: primer pair 1 (Dab1) bridges exons 2 and 3 
of the Dab1 gene, which are shared by Dab555, Dab271 and Dab217, while primer pair 
2 (Dab555), which bridges exons 9 and 10, was designed to detect the Dab555 mRNA 
only (that encodes for the 80 kDa Dab1 protein) [147]. 
For what concern human Dab1 gene, its relative expression was normalized on the 
expression of three housekeeping genes: -Actin, GAPDH and RpL19. As for murine 
samples, the relative expression of Dab1 gene versus the housekeeping gene chosen as 
reference was calculated using the ΔΔCT method [194]. Significance was calculated 
with unpaired student t-test (p-value < 0.05). 
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TARGET PRIMER NAME SEQUENCE (5’-3’) 
AMPLICON 
SIZE (bp) 
ACCESSION 
NUMBER 
REFERENCE 
Mouse 
Dab1 
MoDab1_fw GCCAAGAAAGACTCCAGGAAGA 
79 
NM_177259.4 
NM_010014.3 
 
[147] 
MoDab1_rev GGACCCCTTCGCCTTTAAAC 
Mouse 
Dab1 
MoDab555_fw TTATGATGTGCCAAAAAGTCAACCT 
51 NM_177259.4 [147] 
MoDab555_rev AGTTCTAGTTGGGTCACAGCACTTAC 
Mouse 
-Actin 
MoActb_fw CACACCCGCCACCAGTTC 
164 NM_007393.5 [195] 
MoActb_rev CCCATTCCCACCATCACACC 
Mouse 
III-
Tubulin 
MoTubb3_fw CGCCTTTGGACACCTATTC 
240 NM_023279.2 [196] 
MoTubb3_rev TACTCCTCACGCACCTTG 
Human 
Dab1 
HuDab1_fw CACCGGGCCTTTGGATATGT 
88 NM_021080.3 Designed 
HuDab1_rev GAATAACAGGTTCAGCCGCC 
Human 
-Actin 
HuActb_fw AGAGCTACGAGCTGCCTGAC 
184 NM_001101.3 [197] 
HuActb_rev AGCACTGTGTTGGCGTACAG 
Human 
GAPDH 
HuGAPDH_fw CCTGCACCACCAACTGCTTA 
108 NM_001289746.1 
Modified 
from [198] HuGAPDH_rev TCTTCTGGGTGGCAGTGATG 
Human 
RpL19 
HuRpL19_fw CTAGTGTCCTCCGCTGTGG 
169 NM_000981.3 [199] 
HuRpL19_rev AAGGTGTTTTTCCGGCATC 
Table 6. Primer list for qRT-PCR experiments. (bp = base pairs) 
 
STATISTICAL ANALYSIS 
 
All the results concerning Western Blot analysis of protein expression in mouse brain 
were compared between Prnp+/+ and Prnp0/0 samples performing the Student’s t-Test 
setting two-tailed distribution and two-sample unequal variance. For what concern Fyn 
kinase activation in brain samples, the amount of the phosphorylated protein was 
normalized on the total protein signal and the ratios obtained were compared 
between Prnp+/+ and Prnp0/0 samples performing the Student’s t-Test setting two-
tailed distribution and two-sample unequal variance. The same statistical test was 
applied to reeler mutant mice, ApoER2-/-, VLDLR-/-, ApoER2-/-/VLDLR-/- and Dab1-/- 
samples, comparing each genotype with the respective wild-type control, and to prion-
infected samples compared to non-infected controls. 
Immunoprecipitation experiments (Dab1 protein expression and phosphorylation) 
were analysed as follows. Dab1 expression was measured performing the ratio 
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between immunoprecipitated Dab1 and the starting amount of protein present in the 
input material.  The amount of phosphorylated Dab1 was normalized on total Dab1 
signal. The results of all the experimental replicates were compared between Prnp+/+ 
and Prnp0/0 samples performing the paired Student’s t-Test setting two-tailed 
distribution. 
For primary cultures experiments, in each WB were analysed two technical replicates 
of each treatment, and the average between them was calculated. In order to measure 
Dab1 and Fyn activation after each treatment, the amount of the phosphorylated 
protein was normalized on the total protein signal, and the ratio between Reelin-, 
recMoPrP- or PrP-hFc-treated samples, and mock-, PBS- or hFc- and Rae-1-hFc-
treated controls respectively was performed. The calculated ratios were then 
compared between Prnp+/+ and Prnp0/0 samples performing the Student’s t-Test setting 
two-tailed distribution and two-sample unequal variance. Statistical analysis of 
untreated samples was performed comparing Prnp+/+ and Prnp0/0 cultures performing 
the Student’s t-Test setting two-tailed distribution and two-sample unequal variance. 
Each experiment was performed in triplicate, unless differently specified. 
Statistical significance: p < 0.05. 
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RESULTS 
 
ANALYSIS OF REELIN/DAB1 SIGNALLING PATHWAY ACTIVATION 
STATE IN Prnp+/+ AND Prnp0/0 MOUSE BRAIN DURING EARLY 
POSTNATAL DAYS 
 
As shown in Figure 14, Reelin signalling pathway is triggered by binding of Reelin to its 
transmembrane lipoprotein receptors, ApoER2 and VLDLR, leading to Fyn-mediated 
Dab1 phosphorylation for further downstream signalling transduction [117]. 
Taking advantage of a Prnp knockout mouse model, we addressed the question 
whether PrPC could modulate the Reelin-signalling cascade, and if this is the case, we 
could expect impairments in Reelin downstream signalling when PrPC expression is 
ablated. 
Dab1 is the intracellular adaptor protein that is phosphorylated on tyrosine residues 
upon Reelin binding to its receptors, being the key regulator of Reelin-signalling [131]. 
Indeed, the expression level and the activation state of Dab1 were evaluated in wild-
type (Prnp+/+) and PrPC-null (Prnp0/0) mouse brains. 
 
DAB1 EXPRESSION ANALYSIS 
 
In order to evaluate the existence of a functional interaction between PrPC expression 
and the Reelin pathway, we measured Dab1 expression levels in Prnp+/+ and Prnp0/0 
mouse brain during early postnatal days. Immunoprecipitated Dab1 was normalized on 
input material. Data are shown as ratio between Prnp0/0 and Prnp+/+. In PrPC-null mice, 
Dab1 protein expression is increased of about 40% compared to WT animals, in both 
males and females (Figure 17a). Conversely, transcriptional analysis of mdab1 gene in 
the same samples reveals that Dab1 mRNA expression is not modified by the absence 
of Prnp (Figure 17b). 
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Reelin pathway displays a negative feedback mechanism by which the signal is 
switched off, based on Dab1 poly-ubiquitination and targeting to the proteasome 
[148]. Interestingly, disruption of the Reelin-signalling cascade leads to the 
accumulation of Dab1 protein in vivo, while Dab1 mRNA expression remains 
unchanged [132, 133, 142-145]. As Dab1 degradation is dependent on its 
phosphorylation, the protein tends to accumulate when its phosphorylation is 
impaired [146, 147]. Indeed, having observed Dab1 protein accumulation in our Prnp0/0 
brains, we next sought to analyse Dab1 phosphorylation status in the same samples. 
Taking advantage of immunoprecipitation experiments, we measured the 
phosphorylation status of Dab1 in age- and sex-matched Prnp+/+ and Prnp0/0 mice 
during early postnatal days. Phosphorylated Dab1 protein is normalized on total Dab1 
content in each sample. Data are shown as ratio between Prnp0/0 and Prnp+/+. Due to 
altered expression level of Dab1 in PrPC-null mice and high variability among 
independent experiments, we were not able to obtain convincing results regarding 
Dab1 phosphorylation status in brain samples. Therefore, we decided to take 
advantage of an ex vivo model (see below) (Figure 17c). 
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Figure 17. Dab1 expression and activation state in early postnatal mouse brain. A) Dab1 protein levels 
were measured by immunoprecipitation experiments. Total brain homogenates from P4 Prnp
0/0
 and 
Prnp
+/+
 sex-matched pups were used. Immunoprecipitated Dab1 was normalized on the starting amount 
of protein present in the input material. Sample size in each experiment: n=1; three independent 
experiments for each group (males and females). Data are shown as ratio between Prnp
0/0
 and Prnp
+/+
 ± 
standard error. *p<0.05, **p<0.01, **p<0.001. B) Transcriptional analysis of Dab1 mRNA was performed 
using two couples of primers: Dab1 recognizes all the three murine Dab1 mRNA isoforms, Dab555 
recognizes the longer isoform only. -Actin and III-Tubulin were used as reference genes. Relative 
expression of Dab1 gene versus the housekeeping gene chosen as reference was calculated using the 
ΔΔCT method. Statistical significance: p<0.05. Sample size: n=4 each group. C) Dab1 phosphorylation 
levels were measured by immunoprecipitation experiments. The amount of phosphorylated Dab1 was 
normalized on total Dab1 signal. Sample size in each experiment: n=1; three independent experiments 
for each group (males and females). Data are shown as ratio between Prnp
0/0
 and Prnp
+/+
 ± standard 
error. Statistical significance: p<0.05, n.s. = no statistical significance. 
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REELIN-SIGNALLING PATHWAY EXPRESSION ANALYSIS 
 
Keeping in mind that Dab1 accumulation is observed in conditions of Reelin pathway 
disruption, we hypothesized that alterations in the expression and activation state of 
signalling components may be responsible for the increase in Dab1 protein in Prnp0/0 
mice. Therefore, we performed a protein expression analysis of different components 
of the Reelin-signalling cascade in our PrPC-null mouse model. Each protein signal was 
normalized on -Actin as reference. Data are shown as ratio between Prnp0/0 and 
Prnp+/+. Surprisingly, Reelin, VLDLR and ApoER2 expression levels are not modified in 
Prnp0/0 brains in comparison to WT samples (Figure 18a). Conversely, preliminary data 
showed that phosphorylation of Fyn kinase at tyrosine 416, and thus its activation 
[200], is impaired in Prnp0/0 brains in comparison to WT controls (Figure 18b). 
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Figure 18. Expression and activation state of different component of the Reelin/Dab1 signalling 
pathway in early postnatal mouse brain. A) Reelin, ApoER2, VLDLR and Fyn protein levels were 
measured by WB experiments. Total brain homogenates from P4 Prnp
0/0
 and Prnp
+/+
 sex-matched pups 
were used. -Actin was used as loading control. Sample size in each experiment: n=4; three independent 
experiments. Data are shown as ratio between Prnp
0/0
 and Prnp
+/+
 ± standard error. *p<0.05, **p<0.01, 
**p<0.001, n.s. = no statistical significance. B) Fyn phosphorylation levels in total brain homogenates 
from P4 Prnp
0/0
 and Prnp
+/+
 sex-matched pups were measured by WB experiments. The amount of 
phosphorylated Fyn was normalized on the total protein signal. Sample size in each experiment: n=4; 
one experiment. Data are shown as ratio between Prnp
0/0
 and Prnp
+/+
 ± standard error. *p<0.05, 
**p<0.01, **p<0.001, n.s. = no statistical significance. 
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We next hypothesized that PrPC on the cell membrane could play a role as receptor or 
co-receptor for Reelin, thus modulating its pathway. Interestingly, both PrPC and 
ApoER2 are preferentially located in lipid raft microdomains of the plasma membrane 
[38, 201]. Indeed, co-immunoprecipitation experiments were performed in Prnp+/+ 
brain samples in order to investigate the existence of a direct interaction between PrPC 
and Reelin or its receptor ApoER2. Despite the application of many different 
experimental protocols, described in the Materials and Methods paragraph, we were 
not able to co-immunoprecipitate PrPC neither with Reelin nor with ApoER2 (Figure 
19). 
In order to exclude the possibility that PrPC and ApoER2 may interact at the cell surface 
through a very weak interaction, we decided to perform protein crosslinking of the 
analysed brain samples before proceding with the immunoprecipitation procedure. 
Despite the application of the crosslinking reagent, we were not able to co-
immunoprecipitate PrPC with ApoER2, definitely ruling out the hypothesis of a direct 
interaction between these two proteins in our experimental setup (Figure 20). 
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Figure 19. Co-immunoprecipitation experiments between PrP
C
 and Reelin, and between PrP
C
 and 
ApoER2. PrP
C
, Reelin or ApoER2 were immunoprecipitated from total brain homogenates from P4 
Prnp
+/+
 mice.  Immunoprecipitated samples were then immunoblotted with anti-PrP, anti-ApoER2 and 
anti-Reelin antibodies. Reelin signal in ApoER2-immunoprecipitated samples is considered a positive 
control, and viceversa. 14F2 anti-DISC1 antibody, protein-free hybridoma medium (PFHM) and normal 
mouse/rabbit IgG served as negative control. Starting material (input) was also loaded on the same 
membrane. Sample size in each experiment: n=1; three independent experiments. Three different 
protocols were applied as described (refer to Materials and Methods paragraph for details): A) first 
approach; B) second approach; C) third approach. 
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Figure 20. Co-immunoprecipitation experiments between PrP
C
 and ApoER2 after protein crosslinking. 
Total brain homogenates from P4 mice were treated with DSP crosslinking reagent prior to 
immunoprecipitation.  A) ApoER2 was immunoprecipitated from Prnp
+/+
 brain samples as described. 
Immunoprecipitated samples were then immunoblotted with anti-PrP, anti-ApoER2 and anti-Reelin 
antibodies. Reelin signal in ApoER2-immunoprecipitated samples served as positive control. Rabbit IgG 
served as negative control. Starting material (input), not treated and treated with the crosslinker, was 
also loaded on the same membrane. Sample size in each experiment: n=1; two independent 
experiments. B) PrP
C
 was immunoprecipitated from from Prnp
+/+
 and Prnp
0/0
 brain samples as described. 
Immunoprecipitated samples were then immunoblotted with anti-PrP and anti-ApoER2 antibodies. 
Prnp
0/0
 samples served as negative control. Starting material (input), not treated and treated with the 
crosslinker, was also loaded on the same membrane. Sample size in each experiment: n=1; two 
independent experiments. 
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ANALYSIS OF REELIN/DAB1 SIGNALLING PATHWAY ACTIVATION 
STATE IN Prnp+/+ AND Prnp0/0 PRIMARY NEURONAL CULTURES 
 
As already mentioned, due to increased expression of Dab1 in PrPC-null mice and high 
variability among independent experiments, we were not able to obtain convincing 
results regarding Dab1 phosphorylation status in brain samples. Therefore, we decided 
to take advantage of an ex vivo model based on primary neuronal cultures. Cortical 
primary neurons are commonly used in literature to study Reelin-signalling pathway 
due to the possibility of easy manipulations. Indeed, it has been shown that treatment 
of cultured neurons with Reelin-conditioned supernatant leads to the activation of 
downstream cascade and phosphorylation of Dab1 [133]. We stimulated primary 
cortical neurons from Prnp0/0 and Prnp+/+ embryos with Reelin-conditioned 
supernatant, in order to assess whether the absence of PrPC leads to impairments in 
the response to Reelin. Besides, we also treated these primary cortical neurons with 
recombinant full-length mouse PrP and with the fusion protein moPrP-hFc in order to 
investigate whether PrPC is able to activate Reelin downstream signalling by itself. 
 
STIMULATION WITH REELIN-CONDITIONED MEDIUM 
 
Primary cortical neurons from Prnp0/0 and Prnp+/+ embryos were stimulated after 5 DIV 
with mock- and Reelin-conditioned supernatant, as already described. Reelin content 
in the conditioned medium was evaluated by WB using an anti-Reelin specific antibody 
(Figure 21). 
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Figure 21. Experimental design used for Reelin-stimulation of primary neurons. Primary cortical 
neurons were obtained from E16 Prnp
0/0
 and Prnp
+/+
 embryos and were plated on 6-well plates in 
neurobasal medium (DIV0). After 5 DIV, either neurons were collected under basal conditions or were 
stimulated with mock- or Reelin-conditioned medium. Reelin content in the conditioned medium was 
analysed by WB using anti-Reelin G10 monoclonal antibody (representative image). The same 
experimental design was used for recMoPrP and PrP-hFc treatment. 
 
Dab1 phosphorylation was measured as ratio between phospho-tyrosine signal and 
Dab1 total protein signal. Then, the ratio between Reelin-treated samples and mock-
treated controls was performed. Data are shown as ratio between Prnp0/0 and Prnp+/+. 
In agreement with previous works reported in literature [133], Reelin treatment is able 
to trigger a massive Dab1 phosphorylation in wild-type neurons. Dab1 phosphorylation 
is not modified by PrPC absence under basal conditions. Conversely, Dab1 activation is 
impaired in Prnp0/0 neurons compared to Prnp+/+ controls. Indeed, phosphorylation of 
Dab1 upon Reelin stimulus is reduced by 30% in absence of PrPC (Figure 22). 
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Figure 22. Dab1 phosphorylation in primary cortical neurons upon Reelin stimulus. Dab1 
phosphorylation levels were measured by WB analysis. The amount of phosphorylated Dab1 (pTyr) was 
normalized on the total Dab1 signal, and the ratio between Reelin- and mock-treated samples was 
performed. Sample size in each experiment: n=2 (technical replicates); six independent experiments. 
Data are shown as ratio between Prnp
0/0
 and Prnp
+/+
 ± standard error. *p<0.05, **p<0.01, **p<0.001, 
n.s. = no statistical significance. 
 
In order to assess whether this impairment in Dab1 response is due to alterations in 
the Reelin-signalling pathway, we checked the expression and the activation state of 
different components of the cascade in Prnp0/0 and Prnp+/+ cortical neurons after 5 DIV 
under basal conditions. Western blot analysis revealed that Reelin content in both 
neuron growth media (secreted protein) and neuronal lysate is unchanged in PrPC-null 
neurons compared to WT samples (Figure 23a). Moreover, ApoER2 expression levels 
are not modified by Prnp ablation. Finally, Fyn kinase expression levels are not 
modified in PrPC absence, while its phosphorylation, even without statistical 
significance, showed a decreasing trend in Prnp0/0 neurons compared to WT controls 
(Figure 23b). As Fyn kinase activity could be modulated by NCAM, a known PrPC 
interactor, we decided to measure its expression in the same samples. Interestingly, 
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NCAM expression is reduced by 15% in Prnp0/0 neurons in comparison to WT controls 
(Figure 23c). 
 
 
Figure 23. Expression and activation state of different component of the Reelin/Dab1 signalling 
pathway in E16 primary cortical neurons under basal conditions. A) Reelin expression was measured by 
WB experiments in primary cortical neurons from E16 Prnp
0/0
 and Prnp
+/+
 embryos. Protein expression 
was quantified in both neuronal lysates and neuronal medium after 5 DIV. -Actin was used as loading 
control for lysates. B) ApoER2 protein expression and Fyn kinase expression and phosphorylation levels 
were evaluated by WB experiments in primary cortical neurons from E16 Prnp
0/0
 and Prnp
+/+
 embryos. 
Neuronal lysates after 5 days in vitro were used. -Actin was used as loading control for protein 
expression. The amount of phosphorylated Fyn was normalized on the total protein signal. C) NCAM 
expression was measured by WB experiments in DIV5 primary cortical neurons from E16 Prnp
0/0
 and 
Prnp
+/+
 embryos. -Actin was used as loading control. 
Sample size in each experiment: n=4; two independent experiments. Data are shown as ratio between 
Prnp
0/0
 and Prnp
+/+
 ± standard error. *p<0.05, **p<0.01, **p<0.001, n.s. = no statistical significance. 
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STIMULATION WITH recMoPrP (23-231) AND moPrP-hFc 
 
Taken together, findings obtained from primary neurons stimulated with Reelin 
suggest that PrPC plays a role in modulating Reelin-signalling pathway. Indeed, PrPC 
absence leads to impaired response. Next, we sought to investigate whether PrPC is 
able to activate Reelin downstream signalling cascade, and therefore to promote Dab1 
phosphorylation, by itself. To this aim, we stimulated primary cortical neurons with 
recombinant full-length mouse PrP (recMoPrP 23-231) or with the fusion protein 
moPrP-hFc, a mouse full-length PrP fused with the Fc region of IgG1 human 
immunoglobulin. As described in the Materials and Methods section, recombinant PrP 
is a monomeric protein produced in bacteria, and therefore does not present its 
normal glycosylation pattern but is fully unglycosylated. After purification, a refolding 
protocol allows the recombinant protein to acquire its correct folding. Conversely, 
fusion moPrP-hFc protein is dimeric (two molecules of PrP bound to each arm of the 
antibody Fc region) and oriented, and is produced in eukaryotic cells, therefore it is 
normally present with its typical glycosylation pattern and its physiological folding 
(Figure 24). 
 
 
Figure 24. Schematic representation of PrP
C
, recombinant mouse full-length PrP and moPrP-hFc fusion 
protein. PrP
C
 is a GPI-anchored N-glycosylated protein. The GPI moiety is linked to the C-terminal 
portion of PrP
C
, meaning that PrP
C
 has a fixed orientation on the cell membrane. The recombinant 
mouse full-length PrP is a monomeric and unglycosylated protein. Moreover, it lacks a fixed orientation. 
Fusion moPrP-hFc protein is dimeric and oriented, and it is normally present with its typical 
glycosylation. 
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Figure 25. Recombinant mouse full-length PrP (23-231) and moPrP-hFc fusion protein. A) Western blot 
analysis of 0.1 g of mouse recPrP (23-231) detected with anti-PrP W226 monoclonal antibody. B) 
Western blot analysis of 2 g of moPrP-hFc fusion protein, RAE-1-hFc and hFc. The membrane on the 
left was probed with anti-human HRP-conjugated secondary antibody that recognizes the Fc portion of 
human immunoglobulins. The membrane on the right was probed with anti-PrP W226 monoclonal 
antibody. The molecular weight of hFc alone is about 35 kDa. The two molecular weight bands between 
55 and 70 kDa correspond to the moPrP-hFc fusion protein. 
 
Primary cortical neurons from Prnp0/0 and Prnp+/+ embryos were stimulated after 5 DIV 
with purified recombinant full-length mouse PrP (23-231), adapting a previously 
published protocol to our experimental setup [91]. The integrity of purified 
recombinant MoPrP was assessed by Western blotting using anti-PrP W226 antibody 
(Figure 25a). Two concentration of recMoPrP were tested, as indicated. PBS-treatment 
(vehicle-only) was used as negative control. Dab1 and Fyn kinase phosphorylation was 
measured as ratio between phosphorylated protein and total protein signals. Ratio 
between recMoPrP-treated samples and PBS-treated controls was then performed. 
Data are shown as ratio between Prnp0/0 and Prnp+/+. As shown in Figure 26, 
recombinant MoPrP is not able to induce Fyn kinase and Dab1 phosphorylation, 
neither at 1 M (Figure 26a) nor at 2 M (Figure 26b) concentration. In Figure 26c, 
quantitative analysis of these data is reported. 
 75 
 
Figure 26. Dab1 and Fyn phosphorylation in primary cortical neurons upon recombinant mouse PrP 
treatment. Dab1 and Fyn phosphorylation levels were measured by WB analysis. The amount of 
phosphorylated protein was normalized on the total protein signal, and the ratio between recMoPrP- 
and PBS-treated samples was performed. Sample size in each experiment: n=2 (technical replicates); 
one experiment. A) Neurons treated with 1 M of recMoPrP. B) Neurons treated with 2 M of 
recMoPrP. C) Quantitative analysis of data. Data are shown as ratio between Prnp
0/0
 and Prnp
+/+
. 
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As monomeric recombinant MoPrP failed to activate Reelin downstream cascade by 
itself, we next sought to investigate whether dimeric moPrP-hFc is able to induce Fyn 
kinase activation and, subsequently, Dab1 phosphorylation in dissociated cortical 
neurons. Indeed, moPrP-hFc treatment of primary hippocampal Prnp0/0 and Prnp+/+ 
neurons results in Fyn kinase activation [74]. Thus, we applied the same stimulation 
protocol to our experimental setup, administering moPrP-hFc to primary cortical 
neurons from Prnp0/0 and Prnp+/+ embryos after 5 DIV. Western Blot analysis of purified 
moPrP-hFc allows us to confirm the integrity of the protein used for stimulation (Figure 
25b). Control neurons (mock-treated) were treated with purified human Fc (hFc) or 
with a purified unrelated fusion protein (RAE-1-hFc). Dab1 and Fyn kinase 
phosphorylation was measured as ratio between moPrP-hFc-treated samples and 
mock-treated controls. Data are shown as ratio between Prnp0/0 and Prnp+/+. As shown 
in Figure 27, neither 2 g (Figure 26a) nor 4 g (Figure 26b) of fusion PrP-hFc protein 
are able to induce Fyn kinase and Dab1 phosphorylation. In Figure 27c, quantitative 
analysis of these data is reported. 
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Figure 27. Dab1 and Fyn phosphorylation in primary cortical neurons upon mouse PrP-hFc fusion 
protein treatment. Dab1 and Fyn phosphorylation levels were measured by WB analysis. The amount of 
phosphorylated protein was normalized on the total protein signal, and the ratio between moPrP-hFc- 
and hFc-treated samples was performed. Sample size in each experiment: n=2 (technical replicates); one 
experiment. A) Neurons treated with 2 g of moPrP-hFc and 2 g of hFc as control. B) Neurons treated 
with 4 g of moPrP-hFc and 4 g of hFc as control. C) Quantitative analysis of data. Data are shown as 
ratio between Prnp
0/0
 and Prnp
+/+
. 
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ANALYSIS OF PrPC EXPRESSION IN DIFFERENT MOUSE MODELS OF 
REELIN-SIGNALLING DISRUPTION 
 
Taken together, the data presented above suggest that PrPC is involved in the 
modulation of the Reelin-signalling pathway, boosting the activation of the 
downstream cascade in physiological conditions. Indeed, PrPC absence correlates with 
impaired Dab1 activation upon Reelin stimulation and Dab1 protein accumulation in 
brain samples. Next, we sought to address the opposite question, in order to 
investigate whether Reelin signalling pathway disruption somehow affects PrPC 
expression levels in mouse brain. To this aim, we took advantage of different animal 
models. We measured PrPC expression levels in reeler mutant, ApoER2-/-, VLDLR-/-, 
ApoER2-/-;VLDLR-/- double knockout and Dab1-/- mouse brain during early postnatal 
days. Littermates WT animals were used as controls. For ApoER2-/-;VLDLR-/- double 
knockout mice, VLDLR-/- littermates were used as controls. PrPC expression was 
normalized on -Actin. Data are shown as ratio between mutants and respective 
controls. Due to fertility problems and reduced natality of homozygous mutant mice, 
we were able to collect very few samples for each genotype. PrPC expression was 
measured in three brain regions for each mutant: cortex, cerebellum and 
hippocampus. For what concern reeler mice, PrPC expression was also evaluated in 
total brain homogenate. 
As shown in Figure 28, we were not able to observe statistically significative 
differences in the expression of PrPC in reeler mice, in which Reelin is not expressed. 
We also analysed PrPC expression in mice in which Reelin-signalling pathway is 
disrupted because its receptors have been knocked out. However, PrPC expression 
seems not affected by the lack of ApoER2 (Figure 29) or VLDLR (Figure 30) alone, or by 
the ablation of both of them (Figure 31), in any evaluated brain region. Finally, as we 
observed that PrPC absence determines a significative alteration in Dab1 expression, 
we measured the expression of PrPC in Dab1 knockout mice, to evaluate whether a 
reverse regulatory mechanism between these two proteins also exists in the mouse 
brain. However, as shown in Figure 32, PrPC expression in early postnatal mouse brains 
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is not affected by Dab1 ablation. These findings suggest that PrPC is able to modulate 
Reelin-signalling cascade, but it is not affected by its disruption. 
 
 
Figure 28. PrP
C
 expression in reeler mice. PrP
C
 expression was measured by WB experiments in total 
brain, hippocampus, cortex and cerebellum of P4 reeler mice and littermate WT controls. -Actin was 
used as loading control. Sample size: n=3; one experiment. Data are shown as ratio between reeler and 
WT ± standard error. Statistical significance: p<0.05, n.s. = no statistical significance. 
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Figure 29. PrP
C
 expression in ApoER2
-/-
 mice. PrP
C
 expression was measured by WB experiments in 
hippocampus, cortex and cerebellum of P4 ApoER2
-/-
 mice and littermate WT controls. -Actin was used 
as loading control. Sample size: n=4; one experiment. Data are shown as ratio between ApoER2
-/-
 and 
ApoER2
+/+
 ± standard error. Statistical significance: p<0.05, n.s. = no statistical significance. 
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Figure 30. PrP
C
 expression in VLDLR
-/-
 mice. PrP
C
 expression was measured by WB experiments in 
hippocampus, cortex and cerebellum of P4 VLDLR
-/-
 mice and littermate WT controls. -Actin was used 
as loading control. Sample size: n=4; one experiment. Data are shown as ratio between VLDLR
-/-
 and 
VLDLR
+/+
 ± standard error. Statistical significance: p<0.05, n.s. = no statistical significance. 
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Figure 31. PrP
C
 expression in ApoER2
-/-
;VLDLR
-/-
 mice. PrP
C
 expression was measured by WB 
experiments in hippocampus, cortex and cerebellum of P4 ApoER2
-/-
;VLDLR
-/-
 mice and littermate  
VLDLR
-/-
 controls. -Actin was used as loading control. Sample size: n=4; one experiment. Data are 
shown as ratio between ApoER2
-/-
;VLDLR
-/-
 and VLDLR
-/-
 ± standard error. Statistical significance: p<0.05, 
n.s. = no statistical significance. 
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Figure 32. PrP
C
 expression in Dab1
-/-
 mice. PrP
C
 expression was measured by WB experiments in 
hippocampus, cortex and cerebellum of P4 Dab1
-/-
 mice and littermate WT controls. -Actin was used as 
loading control. Sample size: n=4; one experiment. Data are shown as ratio between Dab1
-/-
 and Dab1
+/+
 
± standard error. Statistical significance: p<0.05, n.s. = no statistical significance. 
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ANALYSIS OF REELIN/DAB1 SIGNALLING PATHWAY IN PRION-
INFECTED MICE 
 
Interestingly, it has been reported that APP processing and β-amyloid deposition in 
sporadic Creutzfeldt-Jakob patients are dependent on Dab1 [185]. In light of this, we 
sought to investigate the effect of prion infection on the Reelin-signalling cascade, 
taking advantage of a mouse model of prion disease. We performed a first experiment 
using five CD1 mice intracerebrally inoculated with RML prion strain at the terminal 
stage of the disease, and five not inoculated age- and sex-matched controls. As already 
mentioned in the Materials and Methods section, these mice were inoculated with 20 
l of RML infected 10% brain homogenate in the striatum. In Table 7, incubation and 
survival times for each animal are reported (see also Figure 33). 
 
LINEAGE 
ANIMAL 
NUMBER 
SEX INOCULUM 
INJECTION 
SITE 
INCUBATION TIME 
(d.p.i.) 
SURVIVAL TIME 
(d.p.i.) 
Crl:CD1 C1 Male RML Striatum 118 132 
Crl:CD1 C2 Male RML Striatum 118 139 
Crl:CD1 C3 Male RML Striatum 121 140 
Crl:CD1 C7 Male RML Striatum 125 153 
Crl:CD1 C16 Female RML Striatum 135 160 
Table 7. Incubation time and survival time of striatum-injected animals. 8-weeks-old CD1 mice were 
inoculated with RML prion strain in the striatum. Incubation time and survival time for each animal is 
reported (d.p.i. = days post infection). 
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Figure 33. Incubation time and survival time of striatum-injected animals. The graphs report the 
incubation time (percentage of symptomatic animals in function of time, expressed as days post 
infection) and the survival time (percentage of alive animals in function of time, expressed as days post 
infection) of 8-weeks-old CD1 mice inoculated with RML prion strain in the striatum, and not-inoculated 
controls. 
 
Taking advantage of Western Blot technique, we measured the expression levels of 
different proteins involved in the Reelin-signalling pathway in brain homogenates 
obtained from these samples. Each protein signal was normalized on -Actin as 
reference. Data are shown as ratio between RML-infected samples and not-inoculated 
controls. As shown in Figure 34a, in terminal stages of prion infection, Dab1 protein 
signal is no longer detectable. This result was also confirmed through 
immunoprecipitation of Dab1 protein from prion infected samples and healthy 
controls (Figure 34b). Given the strong effect caused by prion infection on Dab1 
protein, we evaluated the expression levels of upstream and downstream partners of 
Dab1 on the same samples. As already explained in details, Reelin-signalling pathway is 
triggered by binding of Reelin on its receptors ApoER2 and VLDLR, leading to 
recruitment and activation of Dab1 [117]. Indeed, in order to deeper investigate the 
status of the signalling cascade, we measured the expression of ApoER2 and VLDLR as 
upstream partners of Dab1. As observed for Dab1, ApoER2 and VLDLR proteins are no 
longer detectable in terminally RML infected samples (Figure 34a). Next, we analysed 
the expression levels of NCAM protein, which is also located at the neuronal surface, in 
the same samples. Total expression levels of NCAM are not affected by prion infection, 
but remained unchanged between the two groups of animals. Interestingly, while in 
the control samples both the 180 kDa and 140 kDa NCAM isoforms could be detected, 
enrichment in the 140 kDa, with no detectable 180 kDa isoform, could be observed in 
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RML-infected samples (Figure 34a). As Dab1 activation is mediated by Fyn kinase [133], 
which in turn is modulated by NCAM [74], we next measured Fyn expression levels in 
the same samples. Interestingly, Fyn kinase levels are reduced by more than 30% in 
RML-infected samples compared to controls (Figure 34a). Unfortunately, due to the 
processing without phosphatase inhibitors, it was not possible to analyse Fyn kinase 
activation in these samples. Upon tyrosine phosphorylation, Dab1 can transduce many 
downstream signals. Among them, activated Dab1 could activate PI3K, thus leading to 
the activation of AKT [131, 135-137]. Therefore, as a downstream partner of Dab1, we 
analysed AKT expression levels upon prion infection and we observed a 50% decrease 
in AKT expression in RML-infected samples compared to controls (Figure 34a). 
As the downstream signalling cascade is triggered by Reelin, we next analysed its 
expression in RML-infected samples and matched controls using anti-Reelin mouse 
monoclonal G10 antibody, that recognizes an epitope (amino acids 164-496) located at 
the N-terminal region of the protein. This antibody allows the detection of the full-
length Reelin and two N-terminal fragments obtained by proteolytic cleavage, N-R6 
(about 300 kDa) and N-R2 (about 180 kDa) [129]. We measured the expression of 
Reelin considering the three molecular weight bands altogether or quantifying each 
band separately, performing normalization on -Actin as reference in both cases. 
Notably, the overall amount of Reelin seems not modified by prion infection in 
comparison to control samples. However, measuring separately each detectable band 
of Reelin, it is possible to appreciate pronounced changes in Reelin processing 
between the two groups of animals. Indeed, while full-length 360 kDa protein is 
reduced by almost 50% in RML-infected samples compared to controls, a concomitant 
2-fold increase of both cleavage products is observed (Figure 34c). 
In Figure 34d, statistical analysis of these data is reported. 
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Figure 34. Expression of different component of the Reelin/Dab1 signalling pathway in terminally 
prion diseased striatum-injected mice. A) Total brain homogenates from terminally sick mice and age-
matched controls were analysed by Western Blot for Dab1, ApoER2, VLDLR, NCAM, Fyn and AKT 
expression. -Actin was used as loading control. Sample size: n=5; one experiment. B) 
Immunoprecipitation experiments were performed on total brain homogenates from RML-infected mice 
and age-matched controls to detect Dab1 protein. Sample size in each experiment: n=1; two 
independent experiments. C) Reelin expression was measured in total brain homogenates from 
terminally sick mice and age-matched controls by WB experiments. -Actin was used as loading control. 
Sample size: n=5; one experiment. D) The graph reports the quantification anaysis of the experiments 
shown in A and C. Data are shown as ratio between RML-infected samples and controls  standard 
error. *p<0.05, **p<0.01, ***p<0.001, n.s. = no statistical significance. 
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All these findings were obtained from mice injected with prions in the striatum. In 
order to assess the role of the injection site on the disruption of the Reelin signalling, 
we performed the same analysis on mice inoculated with RML prion strain in the 
hippocampus. We used four CD1 mice intracerebrally inoculated with RML prion strain 
at a pre-symptomatic stage of the disease, four CD1 mice intracerebrally inoculated 
with RML prion strain at the terminal stage of the disease, and four not inoculated age- 
and sex-matched controls, respectively. As already mentioned in the Materials and 
Methods section, these mice were inoculated with 2.5 l of RML infected 10% brain 
homogenate in the hippocampus. In Table 8, survival times for each animal are 
reported (see also Figure 35). 
 
LINEAGE 
ANIMAL 
NUMBER 
SEX INOCULUM INJECTION SITE DISEASE STAGE 
SURVIVAL TIME 
(d.p.i.) 
Crl:CD1 1 Female RML Hippocampus Presymptomatic 97 
Crl:CD1 2 Female RML Hippocampus Presymptomatic 97 
Crl:CD1 3 Female RML Hippocampus Presymptomatic 97 
Crl:CD1 4 Female RML Hippocampus Presymptomatic 97 
Crl:CD1 5 Female RML Hippocampus Presymptomatic 97 
Crl:CD1 6 Female RML Hippocampus Presymptomatic 97 
Crl:CD1 7 Female RML Hippocampus Presymptomatic 97 
Crl:CD1 8 Female RML Hippocampus Presymptomatic 97 
Crl:CD1 9 Female RML Hippocampus Terminal 134 
Crl:CD1 10 Female RML Hippocampus Terminal 134 
Crl:CD1 11 Female RML Hippocampus Terminal 134 
Crl:CD1 12 Female RML Hippocampus Terminal 139 
Crl:CD1 13 Female RML Hippocampus Terminal 145 
Crl:CD1 14 Female RML Hippocampus Terminal 151 
Crl:CD1 15 Female RML Hippocampus Terminal 147 
Crl:CD1 16 Female RML Hippocampus Terminal 147 
Table 8. Incubation time and survival time of hippocampus-injected animals. 8-weeks-old CD1 mice 
were inoculated with RML prion strain in the hippocampus. Disease stage and survival time for each 
animal is reported (d.p.i. = days post infection). Half of the animals were sacrificed 97 d.p.i. (pre-
symptomatic stage of the disease). 
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Figure 35. Survival time of hippocampus-injected animals. The graph shows the survival time 
(percentage of alive animals in function of time, expressed as days post infection) of 8-weeks-old CD1 
mice inoculated with RML prion strain in the hippocampus, and not-inoculated controls. Half of the 
inoculated animals were sacrificed 97 d.p.i. (pre-symptomatic stage of the disease), and respective 
controls were chosen age-matched. 
 
Given the strong effect caused by prion infection on Dab1 protein observed in 
striatum-injected mice, we evaluated Dab1 expression levels in brain homogenates 
obtained from hippocampus-injected samples, both at pre-symptomatic and terminal 
stage of the disease. Dab1 signal was normalized on -Actin as reference. Data are 
shown as ratio between RML-infected samples and age-matched controls. As shown in 
Figure 36a, we were still able to observe a decrease in Dab1 protein expression in 
prion infected animals, both at pre-symptomatic and terminal stage of the disease. 
Indeed, Dab1 protein levels are reduced by 20% in RML-infected samples compared to 
controls, both at pre-symptomatic and terminal stage of the disease. However, Dab1 
downregulation is less pronounced in hippocampus-inoculated animals than that 
observed in the striatum-infected ones, thus suggesting that the site of prion 
inoculation influences the degree of Reelin/Dab1 pathway disruption. 
Next, we analysed mdab1 gene expression by Real Time PCR experiments. However, 
transcriptional analysis of mdab1 gene in the same samples reveals that Dab1 mRNA 
expression is not modified by prion infection (Figure 36b), suggesting that the 
alteration in Dab1 protein expression is due to post-transcriptional mechanisms, 
similarly to what observed in Prnp knockout mice. 
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Figure 36. Dab1 expression in pre-symptomatic and terminally prion diseased hippocampus-injected 
mice. A) Dab1 protein expression was measured by WB experiments in total brain homogenates from 
RML-inoculated mice, at pre-symptomatic and terminal stage of disease, and age-matched controls. -
Actin was used as loading control. Sample size: n=4; one experiment. Data are shown as ratio between 
RML-infected samples and controls  standard error. *p<0.05, **p<0.01, ***p<0.001, n.s. = no 
statistical significance. B) Transcriptional analysis of Dab1 mRNA was performed using two couples of 
primers: Dab1 recognizes all the three murine Dab1 mRNA isoforms, Dab555 recognizes the longer 
isoform only. -Actin and III-Tubulin were used as reference genes. Relative expression of Dab1 gene 
versus the housekeeping gene chosen as reference was calculated using the ΔΔCT method. Sample size: 
n=4; one experiment. Statistical significance: p<0.05. 
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DAB1 GENE EXPRESSION ANALYSIS IN CREUTZFELDT-JAKOB 
DISEASE PATIENTS 
 
Sporadic CJD is described as a prion disease with no known cause, characterized by 
rapid cognitive decline, dementia and ataxia [21]. The type of PrPSc (types 1 and 2) and 
the genotype at codon 129 of the PRNP gene, the site of a methionine/valine 
polymorphism, are crucial determinants of the clinicopathological phenotypes of sCJD 
[23]. As already mentioned, despite the role of Reelin/Dab1 signalling pathway in prion 
diseases has not been deeply investigated, it has been reported that APP processing 
and β-amyloid deposition in sporadic Creutzfeldt-Jakob patients are dependent on 
Dab1. Interestingly, a different effect of Dab1 on Aβ deposition depending PrPSc type in 
human sCJD has been shown [185]. 
Having observed a strong impairment of the Reelin/Dab1 signalling pathway in mouse 
models of prion infection, and knowing that Dab1 phosphorylation plays a role in 
sporadic Creutzfeldt-Jakob disease, we next sought to evaluate whether Dab1 
expression is affected in human sCJD patients. Indeed, we collected postmortem 
frontal cortices derived from four sCJD type 1 patients, four sCJD type 2 patients and 
four healthy controls. Moreover, we analysed Dab1 gene transcription in whole blood 
from two symptomatic sCJD patients and two healthy controls, in an attempt to 
identify Dab1 as a potential biomarker for prion diseases. Unfortunately, 
transcriptional analysis of Dab1 gene revealed that Dab1 mRNA expression is not 
modified by prion infection neither in brain samples (Figure 37) nor in blood (Figure 
38) from sCJD affected patients. In line with these results, we alrealdy observed in 
both Prnp knockout and prion infected mouse samples that the alterations in Dab1 
expression are present at the protein level, while Dab1 gene expression is unchanged, 
thus suggesting that PrPC absence or misfolding affect Dab1 homeostasis at post-
transcriptional level. Indeed, to unravel the involvement of Dab1 in human prion 
diseases, it would be interesting to analyse Dab1 protein expression in human 
samples. 
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Figure 37. Dab1 gene expression in postmortem human sCJD brain samples. Transcriptional analysis of 
Dab1 mRNA was performed using human Dab1 specific primer couple. -Actin, GAPDH and RpL19 were 
used as reference genes. Relative expression of Dab1 gene versus the housekeeping gene chosen as 
reference was calculated using the ΔΔCT method. Statistical significance: p<0.05. Sample size: n=4 each 
group. 
 
 
Figure 38. Dab1 gene expression in human sCJD blood samples. Transcriptional analysis of Dab1 mRNA 
was performed using human Dab1 specific primer couple. -Actin, GAPDH and RpL19 were used as 
reference genes. Relative expression of Dab1 gene versus the housekeeping gene chosen as reference 
was calculated using the ΔΔCT method. Statistical significance: p<0.05. Sample size: n=2 each group. 
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DISCUSSION 
 
The cellular form of the prion protein (PrPC), which is encoded by the endogenous 
gene Prnp, has been deeply investigated since its misfolded isoform, PrPSc, enriched in 
-sheets and with the tendency to form aggregates, is the causative agent of prion 
diseases [2, 37]. Prion diseases, also known as transmissible spongiform 
encephalophaties, are a group of rare and fatal neurodegenerative disorders, 
characterized by sporadic, genetic or infectious etiology, that may affect both animals 
and humans [2, 3, 21]. The pathogenesis of prion diseases is still under debate, as they 
could be gain of toxic function consequences of the formation of PrPSc, or could be due 
to the loss of the normal physiological function of PrPC [4]. According to the gain of 
toxic function hypothesis, the prion pathology is attributable to novel toxic properties 
acquired by PrPSc [14, 15, 38]. Arguing against a direct neurotoxic effect of the 
misfolded protein, PrPSc alone is not sufficient to induce prion disease [16-18]. 
Therefore, it has been proposed that PrPC protective activity may be lost upon 
conversion to PrPSc [38]. However, genetic ablation of Prnp expression results in only 
subtle phenotypic effects and does not induce neurodegeneration by itself [19, 20]. 
Indeed, multiple mechanisms may contribute to the pathology of prion diseases, 
leading to progressive neurodegeneration. In light of this, a better definition of the 
exact physiological function of PrPC represents a critical challenge of the prion field, 
that may help to better understand pathogenetic mechanisms underlying 
neurodegeneration, as well as to propose new therapeutic strategies. 
PrPC is an endogenous glycoprotein, mainly exposed to the outer layer of the cell 
surface as N-glycosylated GPI-anchored protein [31, 32]. Although PrPC is abundantly 
expressed in the developing and mature nervous system [38, 45], it is also expressed in 
many non-neuronal tissues, such as blood lymphocytes, gastro-epithelial cells, heart, 
kidney and muscles, suggesting the involvement of this protein in various physiological 
processes [39, 40]. The high conservation of PrPC among mammalian species suggests 
that it may retain critical physiological roles [22]. Despite many efforts have been done 
in the past years and several PrPC-deficient mouse models have been generated, PrPC 
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physiological function has not been completely characterized. Indeed, Prnp knockout 
models lack striking phenotypes, thus hindering a conclusive definition of the 
physiological functions of PrPC [19, 52]. However, it has been suggested that, in the 
nervous system, PrPC plays a role in modulating sleep-wake cycles, hippocampal-
dependent spatial learning and memory formation. At the cellular level, PrPC 
modulates neurite outgrowth, neuronal excitability and survival, synaptic activity and 
myelin maintenance [21]. 
Of great interest for the present work, PrPC also plays a fundamental role in 
modulating cell signalling, acting as a dynamic scaffold for the assembly of many 
different signalling molecules at the neuronal surface [38, 68, 69]. Indeed, it has been 
shown that PrPC directly interacts with NCAM at the neuronal surface, promoting 
NCAM recruiment to lipid rafts and regulating Fyn kinase activity and neurite 
outgrowth [72, 74]. Moreover, PrPC could also affect PI3K and Akt/PKB activity [100, 
103]. Indeed, it was shown that the recruitment of PI3K by PrPC promotes cell survival 
and, interestingly, PI3K activity was found to be reduced in PrP-null mouse brain 
compared to wild-type animals [100]. These findings, together with reduced 
phosphorylation of AKT in Prnp knockout mice, suggest that PrPC may exert a 
neuroprotective function, and its absence may increase susceptibility to neuronal 
injuries [103]. Finally, more recently, it has also been shown that PrPC promotes GSK3β 
inactivation in a caveolin/Lyn-dependent fashion [95]. All these intracellular kinases 
could be also regulated by an extracellular matrix glycoprotein, named Reelin,  that 
activates a linear downstream signalling pathway. As previously described, Reelin-
signalling pathway is triggered by binding of Reelin on two transmembrane lipoprotein 
receptors, ApoER2 and VLDLR, that promotes the clustering of receptors on the plasma 
membrane and the recruitment of the intracellular adaptor protein Dab1. Upon Fyn-
mediated tyrosine phosphorylation, Dab1 is activated and can transduce various 
downstream signals [117]. 
Interestingly, it has been reported that Reelin-signalling pathway is involved in both 
Alzheimer’s and prion diseases. Indeed, the intracellular adaptor protein Dab1 is able 
to affect APP processing and intracellular trafficking, increasing its -cleavage and 
decreasing A production [182]. Moreover, Dab1 has been shown to influence amyloid 
beta deposition in sporadic Creutzfeldt–Jakob disease [185]. 
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In light of these considerations, this project was aimed to deeper investigate the 
functional interaction between the prion protein and the Reelin/Dab1 signalling 
cascade from a physiological and a pathological point of view. 
 
In the first part of this work, we investigated the role of PrPC in regulating Reelin/Dab1 
signalling taking advantage of Prnp0/0 mice and Prnp+/+ littermate controls. Knowing 
that the expression of both PrPC and Reelin throughout the nervous system is 
developmentally regulated, we decided to carry out the experiments concerning brain 
samples on early postnatal days animals. Indeed, PrPC and Reelin share a similar 
distribution in mammalian brain, being expressed since early stages of brain 
development in cortical and hippocampal structures [45, 158]. PrPC expression 
increases markedly during brain development, starting from the embryogenesis and 
reaching a peak at the end of the synaptogenesis [44]. Reelin is highly expressed by 
Cajal-Retzius neurons during embryogenesis, but its expression is maintained also 
postnatally [117, 158]. Indeed, Reelin is still highly expressed in many cells of the 
cortex and the hippocampus during early postnatal stages [158]. 
Considering that the intracellular adaptor Dab1 represents the key point of Reelin 
downstream signal transduction [117], we initially focused our attention on this 
protein. Indeed, we measured Dab1 expression levels in Prnp knockout mouse brains. 
Our data revealed that Dab1 is strongly upregulated in PrPC-null mice, with an increase 
of about 40% in comparison to wild-type littermates controls. Conversely, 
transcriptional analysis of mdab1 showed that Dab1 gene expression is not influenced 
by the absence of Prnp, suggesting that PrPC absence may affect Dab1 homeostasis at 
post-transcriptional level, influencing its syntesis or stability. It is interesting to note 
that Reelin pathway, as the majority of signalling cascade, displays a negative feedback 
mechanism by which the signal is switched off. For what concern Reelin cascade, this 
desensitization mechanism is based on Dab1 downregulation, which in turn is 
mediated by its poly-ubiquitination and targeting to the proteasome [148]. Indeed, it 
has been shown that disruption of the Reelin-signalling cascade (by genetic ablation of 
Reelin, VLDLR, ApoER2, or Fyn and Src) leads to the accumulation of Dab1 protein in 
vivo, while Dab1 mRNA expression remains unchanged [132, 133, 142-145]. Of note, in 
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our Prnp knockout mice we observed the same situation, characterized by Dab1 
protein accumulation with no changes in its gene transcription. As Prnp ablation 
induces the same effect of Reelin signalling disruption, we can thus hypothesize that 
PrPC may influence Dab1 protein expression by modulating the upstream signalling 
pathway. Therefore, we decided to evaluate the possible alterations in the expression 
and activation status of Reelin pathway signalling components that may be responsible 
for Dab1 upregulation in Prnp0/0 mice. Differently from our expectations, our data 
clearly showed that the expression of Reelin, Reelin receptors ApoER2 and VLDLR, as 
well as Fyn kinase, is not altered by the absence of PrPC. However, the activation of Fyn 
kinase is impaired in Prnp0/0 mice, in agreement with previously reported evidences 
[74]. Fyn kinase recruitment is induced upon Reelin binding to its receptors, leading to 
Dab1 phosphorylation on tyrosine residues [133]. It is known from the literature that 
Dab1 poly-ubiquitination and subsequent degradation is dependent on its 
phosphorylation, thus the protein tends to accumulate when its phosphorylation is 
impaired [146, 147]. The observation that Fyn kinase activation is impaired in Prnp 
knockout mice, together with Dab1 accumulation, is in line with literature and suggests 
that PrPC plays a role in modulating Reelin-signalling pathway. In order to figure out 
whether PrPC may directly influence the signalling cascade by interacting with Reelin or 
its receptors, we performed some co-immunoprecipitation experiments. Interestingly, 
both PrPC and ApoER2 are preferentially located in lipid raft microdomains of the 
plasma membrane [38, 201]. However, we were not able to co-immunoprecipitate 
PrPC with neither Reelin nor ApoER2, ruling out the hypothesis of a direct interaction 
between these proteins.  
Knowing that the activation of Fyn kinase is impaired in Prnp0/0 mice and that Dab1 
protein is upregulated when its phosphorylation is impaired [146, 147], we next sought 
to investigate Dab1 phosphorylation state in Prnp0/0 mice in comparison to Prnp+/+ 
controls. However, due to upregulation of Dab1 in PrPC-null mice and high variability 
among samples, we were not able to obtain convincing results regarding Dab1 
phosphorylation in brain samples. Therefore, we decided to take advantage of an ex 
vivo model based on cultured primary cortical neurons, that are commonly used in 
literature to study Reelin-signalling pathway, as treatment with Reelin-conditioned 
supernatant leads to the activation of the downstream signalling cascade [133]. In 
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agreement with previous works reported in literature [133], Reelin treatment is able to 
trigger a massive Dab1 phosphorylation in Prnp+/+ neurons. Conversely, Dab1 
phosphorylation resulted strongly impaired in Prnp0/0 neurons, that appeared less 
responsive to Reelin stimulation than the wild-type. As already observed in brain 
samples, the impairment in Dab1 response is not due to alterations in the expression 
of Reelin or Reelin receptors, that is not modified by Prnp ablation in neurons under 
basal conditions. However, in line with our previous results on brains, Fyn kinase 
phosphorylation, even without statistical significance, showed a decreasing trend in 
Prnp0/0 neurons compared to WT controls. Indeed, we hypothesized that PrPC may 
indirectly influence Reelin-signalling pathway, and therefore Dab1 expression and 
phosphorylation, by modulating Fyn kinase activity, possibly through interaction with 
NCAM. Indeed, it is well known that PrPC directly interacts with NCAM, modulating Fyn 
kinase activity [72, 74]. In agreement with this hypothesis, we observed a 15% 
reduction in NCAM expression in Prnp0/0 neurons in comparison to WT controls. 
Data obtained from cortical neurons stimulated with Reelin suggest that PrPC plays a 
role in modulating Reelin-signalling pathway, as PrPC absence leads to impaired Dab1 
response. As recombinant PrP added to the culture medium is able to regulate neurite 
outgrowth and to regulate Fyn activation by in trans interaction with NCAM [74, 91], 
we next sought to investigate whether PrPC is able to activate Reelin downstream 
signalling cascade, and therefore to promote Fyn activation and Dab1 phosphorylation, 
by itself. However, in our experimental system, neither recombinant full-length mouse 
PrP nor mouse PrP-hFc fusion protein was able to induce Fyn and Dab1 activation. We 
adjusted the published protocol to our experimental setup that however differs from 
those used in the literature. Indeed, PrP-hFc-mediated Fyn activation was previously 
shown on CHO cells [74], while the modulation of neurite outgrowth induced by 
recombinant PrP was proven on rat embryonic hippocampal neurons [91]. Likely, we 
still need to better adapt these protocols to our murine embryonic cortical neurons in 
order to induce the activation of Fyn and to understand whether PrPC may 
subsequently induce Dab1 phosphorylation by itself. 
Taken together, all these findings suggest that PrPC may influence Reelin cascade, 
promoting the downstream signal transduction, likely modulating Dab1 function 
through NCAM/Fyn pathway. Indeed, Prnp ablation leads to reduced NCAM 
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expression, impaired Fyn activation and, ultimately, impaired Dab1 activation and 
downregulation. Dab1 should be downregulated in neurons to properly terminate 
their migration and to allow the formation of organized layered structures. Indeed, a 
precise regulation of Dab1 levels is required to control the precise location of the 
migration arrest. Impairment of Dab1 downregulation is thus predicted to cause strong 
cortical developmental defects [202]. Indeed, even though neuronal migration defects 
are not yet reported as a phenotype of Prnp knockout mice, it would be interesting to 
perform immunohystochemical analysis to evaluate the presence of subtle differences 
in cortical migration pattern. 
 
In the second part of the project we addressed the opposite question to understand 
whether alteration of the Reelin-signalling pathway could affect the expression of PrPC. 
Indeed, we took advantage of different mouse models of Reelin pathway disruption. 
Among them, the spontaneously arising mutant reeler mouse, in which Reelin 
expression is completely abolished, presents behavioural abnormalities, such as ataxia, 
tremors and reeling gaits [150], due to cerebellar malformation and disrupted laminar 
organization of cortical layers [152]. Moreover, ApoER2 and VLDLR knockout mice, 
together with ApoER2/VLDLR double knockout mice were analysed. As already 
mentioned, while the loss of ApoER2 or VLDLR alone causes only subtle phenotypes, 
the ablation of both receptors causes the reeler phenotype [144]. Finally, as we 
observed that PrPC absence determines a significative alteration in Dab1 expression, 
we measured the expression of PrPC in Dab1 knockout mice, characterized by a reeler 
phenotype [157], to evaluate whether a reverse regulatory mechanism between these 
two proteins also exists in the mouse brain. We decided to carry out this analysis on 
early postnatal days animals, applying the same conditions used for the experiments 
concerning Prnp knockout brain samples. Considering the physiological distribution of 
Reelin during the postnatal period [117], we decided to analyse three brain regions: 
cortex, hippocampus and cerebellum. However, PrPC expression levels did not resulted 
significantly different in none of the genotypes analysed in comparison to their 
respective controls. These findings suggest that, while PrPC is able to modulate Reelin-
signalling cascade and in particular Dab1 activation state, disruption of this pathway 
seems not able to affect PrPC expression. However, we need to take into account that, 
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due to fertility problems and reduced natality of homozygous mutant mice, we were 
able to collect very few samples for each genotype. Therefore, more samples need to 
be collected and analysed to confirm these data. 
 
Finally, in the last part of the project we investigated the functional interaction 
between the prion protein and the Reelin/Dab1 signalling cascade from a pathological 
point of view. Indeed, as already mentioned, the role of the Reelin/Dab1 signalling 
cascade in prion diseases has not been deeply investigated. In order to unravel the 
effect of prion infection on this signalling cascade, RML-inoculated mice were used as 
prion pathology model. Conversely to the Dab1 upregulation observed in Prnp 
knockout mice, prion-infected animals display a complete abolishment of Dab1 protein 
expression, together with the loss of both Reelin receptors. Disruption of the Reelin-
signalling cascade may leads to impaired synaptic function and cytoskeleton dinamics, 
likely contributing to neurodegeneration. Interestingly, the site of prion inoculation 
seems to influence the degree of Reelin/Dab1 pathway disruption. Indeed, less 
pronounced Dab1 downregulation could be observed in hippocampus-inoculated 
animals compared to the striatum-infected ones. However, comparable survival time 
of the two groups of animals suggests that the different effect on Dab1 expression is 
not due to lower levels of infectivity, thus we may hypothesize that it could be due to a 
differential spread of prions throughout brain regions. Interestingly, reduced Dab1 
expression is already pronounced in the pre-symptomatic stage of the infection, thus 
suggesting that Reelin pathway disruption is an early event of prion diseases. Similarly 
to what already observed in Prnp knockout mice, the impairment in Dab1 protein 
expression during prion infection does not correlate with an alteration in its gene 
transcription, suggesting that PrPC misfolding, as PrPC absence, affects Dab1 
homeostasis at post-transcriptional level. 
Interestingly for the present work, it is known from the literature that Dab1 is involved 
in APP processing and β-amyloid deposition in sporadic Creutzfeldt-Jakob patients 
[185]. Having observed a strong impairment of the Reelin/Dab1 signalling pathway in 
mouse models of prion infection, we next evaluated whether Dab1 expression is 
affected in human sCJD patients. As the effect of Dab1 on β-amyloid deposition in sCJD 
is dependent on PrPSc type [185], postmortem frontal cortices from sCJD type 1 
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patients and sCJD type 2 patients, together with whole blood samples from 
symptomatic sCJD patients, were analysed. As shown, transcriptional analysis of Dab1 
gene revealed that its expression is not modified by prion infection neither in brain 
samples nor in blood from sCJD affected patients, thus confirming the results obtained 
in prion infected mouse models. Indeed, to better understand the involvement of 
Dab1 in human prion diseases, it would be interesting to analyse Dab1 protein 
expression in human samples. 
As downstream signalling cascade is triggered by Reelin, we sought to evaluate 
whether its expression is also impaired by prion infection. As already mentioned, upon 
secretion, Reelin is processed by cleavage in two sites located, respectively, between 
repeats 2 and 3 and between repeats 6 and 7. As a result, Reelin is cleaved into five 
fragments that could be discriminated on molecular weight basis [126, 129]. 
Commonly used N-terminal antibodies allow detecting the full-length Reelin and two 
smaller fragments, named N-R6 (about 300 kDa) and N-R2 (about 180 kDa). Indeed, we 
decided to measure the expression of Reelin in prion-infected mice considering the 
three molecular weight bands altogether or quantifying each band separately. Notably, 
the overall amount of Reelin is not modified by prion infection in comparison to 
control samples, while pronounced changes in Reelin processing could be observed. 
Indeed, while full-length 360 kDa protein is reduced by almost 50% in prion-inoculated 
animals compared to controls, a concomitant 2-fold increase of both cleavage 
products is observed. Interestingly, despite the physiological function of the cleavage is 
not fully understood, Reelin processing is thought to play an important role in 
Alzheimer’s disease, as dysfunction of Reelin proteolysis in post-mortem AD tissues 
has been reported [179]. Indeed, increased levels of N-R2 fragment have been 
observed in AD and frontotemporal dementia patients [180, 181]. Our findings suggest 
that Reelin processing may also play a role in prion diseases, thus supporting the 
hypothesis that Reelin-signalling pathway is involved in the pathogenesis of several of 
neurodegenerative diseases. Recently, three enzymes involved in Reelin processing 
have been identified: the serine protease tissue plasminogen activator (tPA), the 
extracellular matrix metalloproteinase ADAMTS-4 and the disintegrin and 
metalloproteinase ADAMTS-5 [127]. Interestingly, PrPSc is specifically recognized by the 
serine protease zymogen plasminogen [203], and recombinant PrP is able to stimulate 
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the activity of tPA in a copper-dependent manner, thus suggesting that tPA-catalyzed 
plasminogen activation may play a role in the pathogenesis of the disease [204]. 
Moreover, both tPA activity and tPA gene expression were found elevated in TSE-
infected brains as compared to healthy controls. Together with the observation that 
the survival time of plasminogen-deficient and tPA-deficient prion-infected mice is 
reduced compared to wild-type animals, these findings suggest that enhanced tPA 
activity observed in prion infected brains may reflect a neuroprotective response 
[205]. Indeed, we may speculate that increased activity of tPA promotes increased 
Reelin processing, that in turn may play a role in the pathogenesis of the disease. 
However, more experiments are needed in order to understand whether increased 
Reelin cleavage has a neuroprotective role during prion diseases or is a secondary 
effect of prion infection. Alternatively, it could be the result of a compensatory 
mechanism due to downstream signalling disruption. 
Interestingly, total expression levels of NCAM are not affected by prion infection, but, 
while in the control samples both the 180 kDa and 140 kDa NCAM isoforms could be 
detected, enrichment in the 140 kDa, with no detectable 180 kDa isoform, could be 
observed in prion-infected mice. NCAM is a cell adhesion macromolecule that exists in 
three major alternatively spliced isoforms (NCAM180kDa, NCAM140kDa, and NCAM120kDa), 
that have different molecular weight, distribution, and function [206, 207]. Indeed, 
distinct roles in synaptic maturation for different NCAM isoforms have been proposed 
[208]. Differential expression of NCAM isoforms has been associated to several 
pathological states, such as tumors [209, 210]. Moreover, overexpression of 
NCAM140kDa isoform, with no changes in NCAM120kDa and NCAM180kDa isoforms has been 
observed in renal fibrosis [211]. Finally, upregulation of NCAM140kDa isoform correlates 
with increased apoptosis of cardiomyocites in ischemic cardiomiopathy, thus having a 
role in the pathogenesis of the disease [212]. Interestingly, we observed an increase in 
the NCAM140kDa isoform in prion-infected animals compared to controls. Even though 
in vivo experiments on NCAM-/- knockout animals failed to show differences in 
incubation time and PrPSc deposition compared to wild-type animals [72], it would be 
interesting to deeper investigate whether differential expression of NCAM isoforms 
plays a role in the pathogenesis of the disease. 
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As Dab1 activation is mediated by Fyn kinase [133], which in turn could be modulated 
by PrPC through NCAM [74], we decided to evaluate the effect of prion infection on 
Fyn expression. Interestingly, we observed a significative reduction in Fyn expression 
levels in prion-inoculated animals. However, Fyn deficiency does not affect PrPSc 
accumulation or the clinical symptoms in mouse models of prion disease, but only 
moderately shortens the survival time, thus suggesting an involvement of Fyn kinase in 
mediating neuroprotective functions [92]. Indeed, the impairment in Fyn kinase 
expression observed in our prion mouse model may result in impaired neuroprotection 
and may contribute to neuronal loss. Unfortunately, it was not possible to analyse Fyn 
kinase activation in these samples, while increased levels of phosphorylated Fyn were 
previously reported both in chronically prion-infected cell lines and in animal models 
of prion disease [93, 94]. In Alzheimer’s disease, it has been shown that increased Fyn 
kinase activity correlates with altered tyrosine phosphorylation of the NR2B subunit of 
NMDAR, that in turn modulates its gating properties, leading to abnormal synaptic 
function and neuronal loss [213]. As increased Fyn kinase activity may contribute to 
synaptic and neuronal loss also in prion diseases [94], experiments aimed to evaluate 
Fyn activation in our mouse models of prion infection are ongoing. 
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CONCLUSIONS AND PERSPECTIVES 
 
In this project, the role of PrPC in Reelin-signalling pathway modulation was 
investigated, taking advantage of Prnp+/+ and Prnp0/0 mice. Expression of different 
components of the cascade was evaluated in early postnatal stages of brain 
development, focusing our attention especially on Dab1 protein and gene expression. 
Furthermore, the activation status of the signalling pathway was investigated in 
primary cortical neurons upon Reelin stimulus. Moreover, different mouse models of 
Reelin-signalling disruption were analyzed for PrPC expression. In the last part of the 
project, the role of Reelin-signalling cascade in mouse models of prion disease and 
human sCJD patients was investigated. 
 
As already discussed, in PrPC loss-of-function mouse models we observed Dab1 protein 
upregulation together with impairment of Fyn kinase activation. Moreover, in Prnp null 
cortical neurons, reduced NCAM expression, reduced Fyn activation and impairment in 
Dab1 activation were detected. Thus, we may propose a model in which, 
physiologically, PrPC modulates the Reelin-signalling pathway indirectly, not physically 
interacting with Reelin or Reelin receptors, but, more likely, through the interaction 
with NCAM and the regulation of Fyn kinase activity, finally influencing Dab1 
phosphorylation and downstream signal transduction. 
 
On the other side, pathological misfolding of PrPC to PrPSc was also shown to play a 
strong effect on the Reelin/Dab1 signalling cascade. Complete disruption of the 
pathway, with ApoER2, VLDLR and Dab1 ablation, together with altered Reelin 
processing, was observed in mouse models of prion disease. Indeed, PrPC misfolding 
seems to play a different role on the Reelin-signalling cascade in comparison to PrPC 
ablation. Therefore, we may speculate that the effects observed in prion infected 
mouse models are not due to the loss-of-physiological-function of PrPC but, more 
likely, PrPSc acquires a different pathological function. 
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Taken together, these findings suggest that, physiologically, PrPC influences Reelin 
cascade, promoting the downstream signal transduction and modulating Dab1 
function through NCAM/Fyn pathway. Pathologically, PrPSc leads to complete Dab1 
signalling disruption, likely contributing to neurodegeneration. Therefore, we shown 
functional interaction between the prion protein and the Reelin/Dab1 signalling 
cascade under physiological and pathological conditions. 
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